

**TDMS No.** 20011 - 05

**Test Type:** CHRONIC

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**Species/Strain:** RATS/F 344

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

1-Bromopropane

**CAS Number:** 106-94-5

**Date Report Requested:** 07/09/2008

**Time Report Requested:** 10:20:06

**First Dose M/F:** 07/14/03 / 07/14/03

**Lab:** BNW

**C Number:** C20011  
**Lock Date:** 06/15/2006  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.0.0

TDMS No. 20011 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 07/09/2008

Time Report Requested: 10:20:06

First Dose M/F: 07/14/03 / 07/14/03

Lab: BNW

## SUMMARY OF STATISTICALLY SIGNIFICANT ( $P \leq .05$ ) RESULTS IN THE ANALYSIS OF 1-Bromopropane

### MALE RATS

#### Organ

Adrenal Cortex

Bone

Harderian Gland

Heart

Heart: Atrium

Kidney: Pelvis

Larynx

Liver

Lung

Lymph Node, Bronchial

Lymph Node, Mediastinal

Nose

Nose: Glands

Pancreas: Acinus

Parathyroid Gland

Pituitary Gland

Preputial Gland

Prostate

Salivary Glands

Skin

Spleen

### FEMALE RATS

#### Organ

Clitoral Gland

#### Morphology

Vacuolization Cytoplasmic

Inflammation Chronic

Inflammation Chronic

Cardiomyopathy

Thrombosis

Inflammation Chronic

Foreign Body

Inflammation Chronic

Clear Cell Focus

Hepatodiaphragmatic Nodule

Inflammation Chronic

Hyperplasia Lymphoid

Angiectasis

Inflammation Chronic

Hyperplasia

Atrophy

Hyperplasia

Hemorrhage

Hyperplasia

Inflammation Chronic

Hyperplasia

Inflammation Chronic

Hyperkeratosis

Inflammation Chronic

Hematopoietic Cell Proliferation

Hemorrhage Chronic

Infarct Chronic

#### Morphology

Hyperplasia

TDMS No. 20011 - 05

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

1-Bromopropane

CAS Number: 106-94-5

Date Report Requested: 07/09/2008

Time Report Requested: 10:20:06

First Dose M/F: 07/14/03 / 07/14/03

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT ( $P \leq .05$ ) RESULTS IN THE ANALYSIS OF 1-Bromopropane

|                              |                                  |
|------------------------------|----------------------------------|
| Harderian Gland              | Inflammation Chronic             |
| Heart                        | Cardiomyopathy                   |
| Islets, Pancreatic           | Hyperplasia                      |
| Larynx                       | Inflammation Chronic             |
|                              | Metaplasia                       |
| Liver                        | Clear Cell Focus                 |
|                              | Vacuolization Cytoplasmic        |
| Lung                         | Inflammation Chronic             |
| Lymph Node, Bronchial        | Angiectasis                      |
| Lymph Node, Mediastinal      | Angiectasis                      |
|                              | Hemorrhage                       |
| Nose                         | Inflammation Chronic             |
| Nose: Glands                 | Hyperplasia                      |
| Nose: Olfactory Epithelium   | Metaplasia Respiratory           |
| Nose: Respiratory Epithelium | Hyperplasia                      |
|                              | Metaplasia                       |
| Oral Mucosa                  | Foreign Body                     |
|                              | Inflammation Chronic             |
| Spleen                       | Hematopoietic Cell Proliferation |
| Stomach, Forestomach         | Hyperplasia                      |
|                              | Ulcer                            |
| Trachea                      | Inflammation Chronic             |
| Trachea: Epithelium          | Hyperplasia                      |
| Uterus                       | Decidual Reaction                |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Adrenal Cortex  
Hyperplasia**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 27/50 (54%) | 21/50 (42%) | 22/50 (44%) | 20/50 (40%) |
| POLY-3 RATE (b)    | 27/44.60    | 21/41.68    | 22/41.74    | 20/38.05    |
| POLY-3 PERCENT (g) | 60.5%       | 50.4%       | 52.7%       | 52.6%       |
| TERMINAL (d)       | 15/23 (65%) | 18/26 (69%) | 8/18 (44%)  | 7/13 (54%)  |
| FIRST INCIDENCE    | 582         | 528         | 418         | 624         |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.299N | P=0.221N | P=0.294N | P=0.296N |
| POLY 1.5           | P=0.218N | P=0.191N | P=0.254N | P=0.202N |
| POLY 6             | P=0.421N | P=0.275N | P=0.350N | P=0.447N |
| COCH-ARM / FISHERS | P=0.135N | P=0.158N | P=0.212N | P=0.115N |
| MAX-ISO-POLY-3     | P=0.359N | P=0.168N | P=0.229N | P=0.237N |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Adrenal Cortex  
Vacuolization Cytoplasmic**

**LESION RATES**

|                    |            |             |            |             |
|--------------------|------------|-------------|------------|-------------|
| OVERALL (a)        | 9/50 (18%) | 16/50 (32%) | 9/50 (18%) | 12/50 (24%) |
| POLY-3 RATE (b)    | 9/42.98    | 16/42.77    | 9/38.92    | 12/38.01    |
| POLY-3 PERCENT (g) | 20.9%      | 37.4%       | 23.1%      | 31.6%       |
| TERMINAL (d)       | 4/23 (17%) | 9/26 (35%)  | 3/18 (17%) | 5/13 (39%)  |
| FIRST INCIDENCE    | 501        | 562         | 603        | 577         |

**STATISTICAL TESTS**

|                    |         |          |          |         |
|--------------------|---------|----------|----------|---------|
| POLY 3             | P=0.313 | P=0.070  | P=0.511  | P=0.199 |
| POLY 1.5           | P=0.379 | P=0.073  | P=0.550  | P=0.241 |
| POLY 6             | P=0.241 | P=0.073  | P=0.466  | P=0.155 |
| COCH-ARM / FISHERS | P=0.477 | P=0.083  | P=0.602N | P=0.312 |
| MAX-ISO-POLY-3     | P=0.249 | P=0.043* | P=0.407  | P=0.148 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Adrenal Medulla  
Hyperplasia**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 23/50 (46%) | 18/50 (36%) | 23/50 (46%) | 19/50 (38%) |
| POLY-3 RATE (b)    | 23/44.02    | 18/42.60    | 23/40.99    | 19/40.46    |
| POLY-3 PERCENT (g) | 52.2%       | 42.3%       | 56.1%       | 47%         |
| TERMINAL (d)       | 12/23 (52%) | 10/26 (39%) | 12/18 (67%) | 5/13 (39%)  |
| FIRST INCIDENCE    | 582         | 562         | 520         | 422         |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.479N | P=0.230N | P=0.442  | P=0.391N |
| POLY 1.5           | P=0.415N | P=0.223N | P=0.505  | P=0.337N |
| POLY 6             | P=0.517  | P=0.238N | P=0.354  | P=0.469N |
| COCH-ARM / FISHERS | P=0.340N | P=0.208N | P=0.579N | P=0.272N |
| MAX-ISO-POLY-3     | P=0.500N | P=0.173N | P=0.358  | P=0.315N |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Bone  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 0/41.44   | 0/40.69   | 0/37.74   | 2/36.62   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 5.5%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | 484       |

**STATISTICAL TESTS**

|                    |          |     |     |         |
|--------------------|----------|-----|-----|---------|
| POLY 3             | P=0.040* | (e) | (e) | P=0.210 |
| POLY 1.5           | P=0.042* | (e) | (e) | P=0.221 |
| POLY 6             | P=0.037* | (e) | (e) | P=0.196 |
| COCH-ARM / FISHERS | P=0.046* | (e) | (e) | P=0.247 |
| MAX-ISO-POLY-3     | P=0.032* | (e) | (e) | P=0.075 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Brain  
Hemorrhage**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 1/50 (2%) | 2/50 (4%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 1/42.05   | 1/41.23   | 2/38.13   | 2/36.30   |
| POLY-3 PERCENT (g) | 2.4%      | 2.4%      | 5.3%      | 5.5%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | 534       | 562       | 666       | 660       |

**STATISTICAL TESTS**

|                    |         |          |         |         |
|--------------------|---------|----------|---------|---------|
| POLY 3             | P=0.278 | P=0.757  | P=0.466 | P=0.449 |
| POLY 1.5           | P=0.303 | P=0.757  | P=0.480 | P=0.470 |
| POLY 6             | P=0.249 | P=0.758  | P=0.448 | P=0.423 |
| COCH-ARM / FISHERS | P=0.337 | P=0.753N | P=0.500 | P=0.500 |
| MAX-ISO-POLY-3     | P=0.408 | P=0.494  | P=0.261 | P=0.253 |



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Coagulating Gland  
Inflammation**

**LESION RATES**

|                    |           |          |          |          |
|--------------------|-----------|----------|----------|----------|
| OVERALL (a)        | 2/3 (67%) | 0/0 (0%) | 0/1 (0%) | 0/2 (0%) |
| POLY-3 RATE (b)    | 2/3.00    | 0/0.00   | 0/1.00   | 0/0.98   |
| POLY-3 PERCENT (g) | 66.7%     | 0%       | 0%       | 0%       |
| TERMINAL (d)       | 0/1 (0%)  | 0/0 (0%) | 0/1 (0%) | 0/0 (0%) |
| FIRST INCIDENCE    | 635       | ---      | ---      | ---      |

**STATISTICAL TESTS**

|                    |          |     |          |          |
|--------------------|----------|-----|----------|----------|
| POLY 3             | (e)      | (e) | P=0.500N | P=0.506N |
| POLY 1.5           | (e)      | (e) | P=0.500N | P=0.422N |
| POLY 6             | (e)      | (e) | P=0.500N | P=0.583N |
| COCH-ARM / FISHERS | P=0.130N | (e) | P=0.500N | P=0.300N |
| MAX-ISO-POLY-3     | (e)      | (e) | P=0.207N | P=0.254N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Eye  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/49 (0%) | 0/49 (0%) | 1/50 (2%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 0/41.24   | 0/40.61   | 1/37.74   | 2/36.95   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 2.7%      | 5.4%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 1/18 (6%) | 0/13 (0%) |
| FIRST INCIDENCE    | ---       | ---       | 729 (T)   | 422       |

**STATISTICAL TESTS**

|                    |         |     |         |         |
|--------------------|---------|-----|---------|---------|
| POLY 3             | P=0.059 | (e) | P=0.482 | P=0.213 |
| POLY 1.5           | P=0.064 | (e) | P=0.491 | P=0.225 |
| POLY 6             | P=0.052 | (e) | P=0.471 | P=0.199 |
| COCH-ARM / FISHERS | P=0.072 | (e) | P=0.505 | P=0.253 |
| MAX-ISO-POLY-3     | P=0.078 | (e) | P=0.159 | P=0.076 |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Eye: Lens  
Cataract**

**LESION RATES**

|                    |           |           |            |           |
|--------------------|-----------|-----------|------------|-----------|
| OVERALL (a)        | 2/49 (4%) | 0/49 (0%) | 3/50 (6%)  | 2/50 (4%) |
| POLY-3 RATE (b)    | 2/41.24   | 0/40.61   | 3/38.38    | 2/36.56   |
| POLY-3 PERCENT (g) | 4.9%      | 0%        | 7.8%       | 5.5%      |
| TERMINAL (d)       | 2/23 (9%) | 0/26 (0%) | 2/18 (11%) | 1/13 (8%) |
| FIRST INCIDENCE    | 729 (T)   | ---       | 520        | 453       |

**STATISTICAL TESTS**

|                    |         |          |         |          |
|--------------------|---------|----------|---------|----------|
| POLY 3             | P=0.367 | P=0.240N | P=0.467 | P=0.650  |
| POLY 1.5           | P=0.394 | P=0.239N | P=0.485 | P=0.672  |
| POLY 6             | P=0.333 | P=0.239N | P=0.446 | P=0.622  |
| COCH-ARM / FISHERS | P=0.432 | P=0.247N | P=0.510 | P=0.684N |
| MAX-ISO-POLY-3     | P=0.323 | P=0.079N | P=0.301 | P=0.453  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Harderian Gland  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 0/41.44   | 0/40.69   | 0/37.74   | 2/36.64   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 5.5%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | 453       |

**STATISTICAL TESTS**

|                    |          |     |     |         |
|--------------------|----------|-----|-----|---------|
| POLY 3             | P=0.040* | (e) | (e) | P=0.210 |
| POLY 1.5           | P=0.042* | (e) | (e) | P=0.221 |
| POLY 6             | P=0.037* | (e) | (e) | P=0.196 |
| COCH-ARM / FISHERS | P=0.046* | (e) | (e) | P=0.247 |
| MAX-ISO-POLY-3     | P=0.032* | (e) | (e) | P=0.075 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Heart  
Cardiomyopathy**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 26/50 (52%) | 23/50 (46%) | 23/50 (46%) | 15/50 (30%) |
| POLY-3 RATE (b)    | 26/44.30    | 23/42.33    | 23/41.39    | 15/38.01    |
| POLY-3 PERCENT (g) | 58.7%       | 54.3%       | 55.6%       | 39.5%       |
| TERMINAL (d)       | 17/23 (74%) | 17/26 (65%) | 11/18 (61%) | 7/13 (54%)  |
| FIRST INCIDENCE    | 429         | 569         | 520         | 527         |

**STATISTICAL TESTS**

|                    |           |          |          |           |
|--------------------|-----------|----------|----------|-----------|
| POLY 3             | P=0.047N* | P=0.420N | P=0.469N | P=0.054N  |
| POLY 1.5           | P=0.030N* | P=0.396N | P=0.417N | P=0.036N* |
| POLY 6             | P=0.081N  | P=0.429N | P=0.522N | P=0.085N  |
| COCH-ARM / FISHERS | P=0.016N* | P=0.345N | P=0.345N | P=0.021N* |
| MAX-ISO-POLY-3     | P=0.069N  | P=0.337N | P=0.381N | P=0.042N* |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Heart: Atrium  
Thrombosis**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 4/50 (8%) | 0/50 (0%) | 0/50 (0%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 4/42.29   | 0/40.69   | 0/37.74   | 2/36.06   |
| POLY-3 PERCENT (g) | 9.5%      | 0%        | 0%        | 5.6%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 1/13 (8%) |
| FIRST INCIDENCE    | 646       | ---       | ---       | 659       |

**STATISTICAL TESTS**

|                    |          |           |           |          |
|--------------------|----------|-----------|-----------|----------|
| POLY 3             | P=0.340N | P=0.065N  | P=0.075N  | P=0.412N |
| POLY 1.5           | P=0.337N | P=0.063N  | P=0.068N  | P=0.380N |
| POLY 6             | P=0.346N | P=0.066N  | P=0.086N  | P=0.458N |
| COCH-ARM / FISHERS | P=0.337N | P=0.059N  | P=0.059N  | P=0.339N |
| MAX-ISO-POLY-3     | P=0.076N | P=0.023N* | P=0.032N* | P=0.275N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Islets, Pancreatic  
Hyperplasia**

**LESION RATES**

|                    |             |            |            |            |
|--------------------|-------------|------------|------------|------------|
| OVERALL (a)        | 10/50 (20%) | 7/50 (14%) | 6/50 (12%) | 9/50 (18%) |
| POLY-3 RATE (b)    | 10/42.86    | 7/41.46    | 6/38.78    | 9/38.21    |
| POLY-3 PERCENT (g) | 23.3%       | 16.9%      | 15.5%      | 23.6%      |
| TERMINAL (d)       | 5/23 (22%)  | 5/26 (19%) | 4/18 (22%) | 1/13 (8%)  |
| FIRST INCIDENCE    | 591         | 568        | 534        | 453        |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.509  | P=0.320N | P=0.268N | P=0.595  |
| POLY 1.5           | P=0.549  | P=0.312N | P=0.239N | P=0.567N |
| POLY 6             | P=0.453  | P=0.326N | P=0.314N | P=0.540  |
| COCH-ARM / FISHERS | P=0.500N | P=0.298N | P=0.207N | P=0.500N |
| MAX-ISO-POLY-3     | P=0.480  | P=0.233N | P=0.196N | P=0.490  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Islets, Pancreatic  
Metaplasia Hepatocyte**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 0/41.44   | 0/40.69   | 0/37.74   | 0/35.80   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 0%        |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | ---       |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Kidney  
Nephropathy Chronic**

**LESION RATES**

|                    |              |              |             |              |
|--------------------|--------------|--------------|-------------|--------------|
| OVERALL (a)        | 44/50 (88%)  | 45/50 (90%)  | 39/50 (78%) | 44/49 (90%)  |
| POLY-3 RATE (b)    | 44/47.89     | 45/46.75     | 39/44.62    | 44/45.75     |
| POLY-3 PERCENT (g) | 91.9%        | 96.3%        | 87.4%       | 96.2%        |
| TERMINAL (d)       | 23/23 (100%) | 26/26 (100%) | 17/18 (94%) | 13/13 (100%) |
| FIRST INCIDENCE    | 534          | 528          | 514         | 422          |

**STATISTICAL TESTS**

|                    |          |         |          |         |
|--------------------|----------|---------|----------|---------|
| POLY 3             | P=0.358  | P=0.287 | P=0.333N | P=0.301 |
| POLY 1.5           | P=0.450  | P=0.373 | P=0.220N | P=0.383 |
| POLY 6             | P=0.266  | P=0.204 | P=0.563N | P=0.244 |
| COCH-ARM / FISHERS | P=0.553N | P=0.500 | P=0.143N | P=0.514 |
| MAX-ISO-POLY-3     | P=0.250  | P=0.141 | P=0.210N | P=0.153 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Kidney: Cortex, Renal Tubule  
Casts Granular**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 2/50 (4%) | 0/49 (0%) |
| POLY-3 RATE (b)    | 0/41.44   | 0/40.69   | 2/38.63   | 0/35.06   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 5.2%      | 0%        |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | ---       | ---       | 578       | ---       |

**STATISTICAL TESTS**

|                    |         |     |         |     |
|--------------------|---------|-----|---------|-----|
| POLY 3             | P=0.513 | (e) | P=0.221 | (e) |
| POLY 1.5           | P=0.547 | (e) | P=0.228 | (e) |
| POLY 6             | P=0.468 | (e) | P=0.214 | (e) |
| COCH-ARM / FISHERS | P=0.591 | (e) | P=0.247 | (e) |
| MAX-ISO-POLY-3     | P=0.267 | (e) | P=0.075 | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Kidney: Pelvis  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 2/49 (4%) |
| POLY-3 RATE (b)    | 0/41.44   | 0/40.69   | 0/37.74   | 2/35.17   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 5.7%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 1/13 (8%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | 701       |

**STATISTICAL TESTS**

|                    |          |     |     |         |
|--------------------|----------|-----|-----|---------|
| POLY 3             | P=0.038* | (e) | (e) | P=0.202 |
| POLY 1.5           | P=0.040* | (e) | (e) | P=0.214 |
| POLY 6             | P=0.035* | (e) | (e) | P=0.187 |
| COCH-ARM / FISHERS | P=0.045* | (e) | (e) | P=0.242 |
| MAX-ISO-POLY-3     | P=0.031* | (e) | (e) | P=0.074 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

Larynx  
Foreign Body

**LESION RATES**

|                    |            |           |            |           |
|--------------------|------------|-----------|------------|-----------|
| OVERALL (a)        | 6/50 (12%) | 1/50 (2%) | 5/50 (10%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 6/42.19    | 1/41.06   | 5/39.05    | 1/36.42   |
| POLY-3 PERCENT (g) | 14.2%      | 2.4%      | 12.8%      | 2.8%      |
| TERMINAL (d)       | 3/23 (13%) | 0/26 (0%) | 1/18 (6%)  | 0/13 (0%) |
| FIRST INCIDENCE    | 501        | 624       | 561        | 527       |

**STATISTICAL TESTS**

|                    |          |           |          |           |
|--------------------|----------|-----------|----------|-----------|
| POLY 3             | P=0.126N | P=0.059N  | P=0.555N | P=0.081N  |
| POLY 1.5           | P=0.111N | P=0.059N  | P=0.532N | P=0.070N  |
| POLY 6             | P=0.150N | P=0.057N  | P=0.579N | P=0.098N  |
| COCH-ARM / FISHERS | P=0.095N | P=0.056N  | P=0.500N | P=0.056N  |
| MAX-ISO-POLY-3     | P=0.064N | P=0.026N* | P=0.427N | P=0.046N* |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Larynx  
Inflammation Chronic**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 21/50 (42%) | 28/50 (56%) | 31/50 (62%) | 27/50 (54%) |
| POLY-3 RATE (b)    | 21/44.09    | 28/45.59    | 31/45.51    | 27/44.93    |
| POLY-3 PERCENT (g) | 47.6%       | 61.4%       | 68.1%       | 60.1%       |
| TERMINAL (d)       | 11/23 (48%) | 13/26 (50%) | 9/18 (50%)  | 6/13 (46%)  |
| FIRST INCIDENCE    | 501         | 560         | 488         | 394         |

**STATISTICAL TESTS**

|                    |         |         |          |         |
|--------------------|---------|---------|----------|---------|
| POLY 3             | P=0.169 | P=0.127 | P=0.032* | P=0.157 |
| POLY 1.5           | P=0.170 | P=0.115 | P=0.031* | P=0.156 |
| POLY 6             | P=0.170 | P=0.164 | P=0.042* | P=0.165 |
| COCH-ARM / FISHERS | P=0.175 | P=0.115 | P=0.036* | P=0.158 |
| MAX-ISO-POLY-3     | P=0.080 | P=0.091 | P=0.021* | P=0.112 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Larynx  
Metaplasia**

**LESION RATES**

|                    |           |            |            |            |
|--------------------|-----------|------------|------------|------------|
| OVERALL (a)        | 4/50 (8%) | 6/50 (12%) | 8/50 (16%) | 5/50 (10%) |
| POLY-3 RATE (b)    | 4/42.14   | 6/42.36    | 8/40.43    | 5/37.07    |
| POLY-3 PERCENT (g) | 9.5%      | 14.2%      | 19.8%      | 13.5%      |
| TERMINAL (d)       | 2/23 (9%) | 2/26 (8%)  | 1/18 (6%)  | 1/13 (8%)  |
| FIRST INCIDENCE    | 501       | 585        | 561        | 562        |

**STATISTICAL TESTS**

|                    |         |         |         |         |
|--------------------|---------|---------|---------|---------|
| POLY 3             | P=0.332 | P=0.372 | P=0.153 | P=0.419 |
| POLY 1.5           | P=0.381 | P=0.367 | P=0.162 | P=0.452 |
| POLY 6             | P=0.278 | P=0.388 | P=0.148 | P=0.383 |
| COCH-ARM / FISHERS | P=0.455 | P=0.370 | P=0.178 | P=0.500 |
| MAX-ISO-POLY-3     | P=0.313 | P=0.254 | P=0.095 | P=0.300 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Liver  
Angiectasis**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 2/50 (4%) | 1/50 (2%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 0/41.44   | 2/40.69   | 1/37.87   | 0/35.80   |
| POLY-3 PERCENT (g) | 0%        | 4.9%      | 2.6%      | 0%        |
| TERMINAL (d)       | 0/23 (0%) | 2/26 (8%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | ---       | 729 (T)   | 697       | ---       |

**STATISTICAL TESTS**

|                    |          |         |         |     |
|--------------------|----------|---------|---------|-----|
| POLY 3             | P=0.514N | P=0.233 | P=0.482 | (e) |
| POLY 1.5           | P=0.492N | P=0.234 | P=0.490 | (e) |
| POLY 6             | P=0.545N | P=0.233 | P=0.472 | (e) |
| COCH-ARM / FISHERS | P=0.461N | P=0.247 | P=0.500 | (e) |
| MAX-ISO-POLY-3     | P=0.355  | P=0.075 | P=0.158 | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Liver  
Basophilic Focus**

**LESION RATES**

|                    |            |            |            |            |
|--------------------|------------|------------|------------|------------|
| OVERALL (a)        | 9/50 (18%) | 9/50 (18%) | 8/50 (16%) | 8/50 (16%) |
| POLY-3 RATE (b)    | 9/41.83    | 9/41.08    | 8/37.74    | 8/35.93    |
| POLY-3 PERCENT (g) | 21.5%      | 21.9%      | 21.2%      | 22.3%      |
| TERMINAL (d)       | 7/23 (30%) | 8/26 (31%) | 8/18 (44%) | 7/13 (54%) |
| FIRST INCIDENCE    | 653        | 618        | 729 (T)    | 697        |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.525  | P=0.589  | P=0.595N | P=0.578  |
| POLY 1.5           | P=0.508N | P=0.591  | P=0.552N | P=0.580N |
| POLY 6             | P=0.428  | P=0.594  | P=0.567  | P=0.498  |
| COCH-ARM / FISHERS | P=0.424N | P=0.602N | P=0.500N | P=0.500N |
| MAX-ISO-POLY-3     | P=0.714  | P=0.482  | P=0.486N | P=0.469  |

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

Liver  
Clear Cell Focus

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 16/50 (32%) | 25/50 (50%) | 17/50 (34%) | 15/50 (30%) |
| POLY-3 RATE (b)    | 16/42.40    | 25/41.09    | 17/39.08    | 15/37.44    |
| POLY-3 PERCENT (g) | 37.7%       | 60.8%       | 43.5%       | 40.1%       |
| TERMINAL (d)       | 11/23 (48%) | 23/26 (89%) | 13/18 (72%) | 8/13 (62%)  |
| FIRST INCIDENCE    | 635         | 627         | 514         | 562         |

**STATISTICAL TESTS**

|                    |          |          |         |          |
|--------------------|----------|----------|---------|----------|
| POLY 3             | P=0.397N | P=0.022* | P=0.377 | P=0.507  |
| POLY 1.5           | P=0.312N | P=0.031* | P=0.433 | P=0.577  |
| POLY 6             | P=0.527N | P=0.012* | P=0.299 | P=0.412  |
| COCH-ARM / FISHERS | P=0.221N | P=0.052  | P=0.500 | P=0.500N |
| MAX-ISO-POLY-3     | P=0.273  | P=0.013* | P=0.300 | P=0.416  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Liver  
Degeneration Cystic**

**LESION RATES**

|                    |           |           |           |            |
|--------------------|-----------|-----------|-----------|------------|
| OVERALL (a)        | 2/50 (4%) | 2/50 (4%) | 1/50 (2%) | 4/50 (8%)  |
| POLY-3 RATE (b)    | 2/41.44   | 2/40.95   | 1/38.44   | 4/35.80    |
| POLY-3 PERCENT (g) | 4.8%      | 4.9%      | 2.6%      | 11.2%      |
| TERMINAL (d)       | 2/23 (9%) | 1/26 (4%) | 0/18 (0%) | 4/13 (31%) |
| FIRST INCIDENCE    | 729 (T)   | 660       | 488       | 729 (T)    |

**STATISTICAL TESTS**

|                    |         |          |          |         |
|--------------------|---------|----------|----------|---------|
| POLY 3             | P=0.184 | P=0.690  | P=0.526N | P=0.271 |
| POLY 1.5           | P=0.202 | P=0.690  | P=0.515N | P=0.298 |
| POLY 6             | P=0.162 | P=0.695  | P=0.541N | P=0.236 |
| COCH-ARM / FISHERS | P=0.227 | P=0.691N | P=0.500N | P=0.339 |
| MAX-ISO-POLY-3     | P=0.176 | P=0.494  | P=0.308N | P=0.167 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

Liver  
Hepatodiaphragmatic Nodule

**LESION RATES**

|                    |            |           |           |           |
|--------------------|------------|-----------|-----------|-----------|
| OVERALL (a)        | 4/50 (8%)  | 1/50 (2%) | 0/50 (0%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 4/41.70    | 1/40.69   | 0/37.74   | 2/36.40   |
| POLY-3 PERCENT (g) | 9.6%       | 2.5%      | 0%        | 5.5%      |
| TERMINAL (d)       | 3/23 (13%) | 1/26 (4%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | 660        | 729 (T)   | ---       | 635       |

**STATISTICAL TESTS**

|                    |          |          |           |          |
|--------------------|----------|----------|-----------|----------|
| POLY 3             | P=0.294N | P=0.185N | P=0.073N  | P=0.401N |
| POLY 1.5           | P=0.286N | P=0.184N | P=0.067N  | P=0.374N |
| POLY 6             | P=0.305N | P=0.184N | P=0.081N  | P=0.435N |
| COCH-ARM / FISHERS | P=0.279N | P=0.181N | P=0.059N  | P=0.339N |
| MAX-ISO-POLY-3     | P=0.128N | P=0.090N | P=0.030N* | P=0.264N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Liver  
Mixed Cell Focus**

**LESION RATES**

|                    |           |           |            |           |
|--------------------|-----------|-----------|------------|-----------|
| OVERALL (a)        | 2/50 (4%) | 1/50 (2%) | 3/50 (6%)  | 0/50 (0%) |
| POLY-3 RATE (b)    | 2/41.70   | 1/40.69   | 3/37.90    | 0/35.80   |
| POLY-3 PERCENT (g) | 4.8%      | 2.5%      | 7.9%       | 0%        |
| TERMINAL (d)       | 1/23 (4%) | 1/26 (4%) | 2/18 (11%) | 0/13 (0%) |
| FIRST INCIDENCE    | 660       | 729 (T)   | 688        | ---       |

**STATISTICAL TESTS**

|                    |          |          |         |          |
|--------------------|----------|----------|---------|----------|
| POLY 3             | P=0.296N | P=0.509N | P=0.456 | P=0.272N |
| POLY 1.5           | P=0.272N | P=0.506N | P=0.475 | P=0.257N |
| POLY 6             | P=0.332N | P=0.509N | P=0.431 | P=0.294N |
| COCH-ARM / FISHERS | P=0.242N | P=0.500N | P=0.500 | P=0.247N |
| MAX-ISO-POLY-3     | P=0.235N | P=0.290N | P=0.293 | P=0.109N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

Liver  
Necrosis

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 2/50 (4%) | 1/50 (2%) | 1/50 (2%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 2/41.98   | 1/41.17   | 1/37.87   | 1/36.06   |
| POLY-3 PERCENT (g) | 4.8%      | 2.4%      | 2.6%      | 2.8%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | 646       | 585       | 697       | 659       |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.446N | P=0.507N | P=0.536N | P=0.553N |
| POLY 1.5           | P=0.430N | P=0.505N | P=0.520N | P=0.531N |
| POLY 6             | P=0.468N | P=0.506N | P=0.557N | P=0.582N |
| COCH-ARM / FISHERS | P=0.409N | P=0.500N | P=0.500N | P=0.500N |
| MAX-ISO-POLY-3     | P=0.494N | P=0.288N | P=0.319N | P=0.336N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Liver  
Vacuolization Cytoplasmic**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 31/50 (62%) | 38/50 (76%) | 32/50 (64%) | 37/50 (74%) |
| POLY-3 RATE (b)    | 31/46.22    | 38/47.40    | 32/46.52    | 37/46.10    |
| POLY-3 PERCENT (g) | 67.1%       | 80.2%       | 68.8%       | 80.3%       |
| TERMINAL (d)       | 15/23 (65%) | 24/26 (92%) | 11/18 (61%) | 12/13 (92%) |
| FIRST INCIDENCE    | 429         | 316         | 418         | 394         |

**STATISTICAL TESTS**

|                    |         |         |         |         |
|--------------------|---------|---------|---------|---------|
| POLY 3             | P=0.160 | P=0.100 | P=0.519 | P=0.099 |
| POLY 1.5           | P=0.181 | P=0.099 | P=0.511 | P=0.113 |
| POLY 6             | P=0.137 | P=0.099 | P=0.528 | P=0.082 |
| COCH-ARM / FISHERS | P=0.219 | P=0.097 | P=0.500 | P=0.142 |
| MAX-ISO-POLY-3     | P=0.097 | P=0.065 | P=0.425 | P=0.061 |

---

TDMS No. 20011 - 05  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 1-Bromopropane  
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008  
 Time Report Requested: 10:20:06  
 First Dose M/F: 07/14/03 / 07/14/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lung  
 Hemorrhage**

**LESION RATES**

|                    |           |            |           |           |
|--------------------|-----------|------------|-----------|-----------|
| OVERALL (a)        | 2/50 (4%) | 5/50 (10%) | 1/50 (2%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 2/42.38   | 5/40.94    | 1/38.24   | 1/35.80   |
| POLY-3 PERCENT (g) | 4.7%      | 12.2%      | 2.6%      | 2.8%      |
| TERMINAL (d)       | 0/23 (0%) | 4/26 (15%) | 0/18 (0%) | 1/13 (8%) |
| FIRST INCIDENCE    | 501       | 663        | 578       | 729 (T)   |

**STATISTICAL TESTS**

|                    |          |         |          |          |
|--------------------|----------|---------|----------|----------|
| POLY 3             | P=0.253N | P=0.201 | P=0.536N | P=0.558N |
| POLY 1.5           | P=0.226N | P=0.206 | P=0.520N | P=0.534N |
| POLY 6             | P=0.292N | P=0.198 | P=0.556N | P=0.591N |
| COCH-ARM / FISHERS | P=0.194N | P=0.218 | P=0.500N | P=0.500N |
| MAX-ISO-POLY-3     | P=0.257N | P=0.112 | P=0.319N | P=0.343N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lung  
Inflammation Chronic**

**LESION RATES**

|                    |            |           |           |            |
|--------------------|------------|-----------|-----------|------------|
| OVERALL (a)        | 5/50 (10%) | 0/50 (0%) | 1/50 (2%) | 6/50 (12%) |
| POLY-3 RATE (b)    | 5/43.25    | 0/40.69   | 1/38.21   | 6/39.67    |
| POLY-3 PERCENT (g) | 11.6%      | 0%        | 2.6%      | 15.1%      |
| TERMINAL (d)       | 1/23 (4%)  | 0/26 (0%) | 0/18 (0%) | 0/13 (0%)  |
| FIRST INCIDENCE    | 501        | ---       | 590       | 422        |

**STATISTICAL TESTS**

|                    |         |           |          |         |
|--------------------|---------|-----------|----------|---------|
| POLY 3             | P=0.192 | P=0.035N* | P=0.131N | P=0.439 |
| POLY 1.5           | P=0.200 | P=0.034N* | P=0.118N | P=0.465 |
| POLY 6             | P=0.179 | P=0.037N* | P=0.150N | P=0.402 |
| COCH-ARM / FISHERS | P=0.210 | P=0.028N* | P=0.102N | P=0.500 |
| MAX-ISO-POLY-3     | P=0.062 | P=0.013N* | P=0.072N | P=0.323 |

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lung: Alveolar Epithelium  
Hyperplasia**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 15/50 (30%) | 11/50 (22%) | 13/50 (26%) | 11/50 (22%) |
| POLY-3 RATE (b)    | 15/44.57    | 11/42.92    | 13/40.29    | 11/38.55    |
| POLY-3 PERCENT (g) | 33.7%       | 25.6%       | 32.3%       | 28.5%       |
| TERMINAL (d)       | 7/23 (30%)  | 5/26 (19%)  | 5/18 (28%)  | 3/13 (23%)  |
| FIRST INCIDENCE    | 501         | 505         | 534         | 500         |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.424N | P=0.276N | P=0.538N | P=0.394N |
| POLY 1.5           | P=0.358N | P=0.266N | P=0.483N | P=0.331N |
| POLY 6             | P=0.512N | P=0.285N | P=0.581  | P=0.477N |
| COCH-ARM / FISHERS | P=0.272N | P=0.247N | P=0.412N | P=0.247N |
| MAX-ISO-POLY-3     | P=0.504N | P=0.208N | P=0.447N | P=0.318N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lung: Alveolus  
Infiltration Cellular Histiocyte**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 16/50 (32%) | 14/50 (28%) | 13/50 (26%) | 11/50 (22%) |
| POLY-3 RATE (b)    | 16/44.53    | 14/43.31    | 13/40.09    | 11/38.45    |
| POLY-3 PERCENT (g) | 35.9%       | 32.3%       | 32.4%       | 28.6%       |
| TERMINAL (d)       | 7/23 (30%)  | 7/26 (27%)  | 5/18 (28%)  | 3/13 (23%)  |
| FIRST INCIDENCE    | 501         | 562         | 520         | 484         |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.281N | P=0.447N | P=0.456N | P=0.315N |
| POLY 1.5           | P=0.221N | P=0.438N | P=0.400N | P=0.256N |
| POLY 6             | P=0.371N | P=0.449N | P=0.530N | P=0.398N |
| COCH-ARM / FISHERS | P=0.153N | P=0.414N | P=0.330N | P=0.184N |
| MAX-ISO-POLY-3     | P=0.405N | P=0.360N | P=0.371N | P=0.251N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node, Bronchial  
Angiectasis**

**LESION RATES**

|                    |           |           |            |          |
|--------------------|-----------|-----------|------------|----------|
| OVERALL (a)        | 1/3 (33%) | 2/6 (33%) | 2/5 (40%)  | 0/8 (0%) |
| POLY-3 RATE (b)    | 1/2.29    | 2/4.76    | 2/4.11     | 0/5.41   |
| POLY-3 PERCENT (g) | 43.7%     | 42%       | 48.6%      | 0%       |
| TERMINAL (d)       | 0/0 (0%)  | 0/0 (0%)  | 1/1 (100%) | 0/2 (0%) |
| FIRST INCIDENCE    | 669       | 660       | 697        | ---      |

**STATISTICAL TESTS**

|                    |          |          |         |          |
|--------------------|----------|----------|---------|----------|
| POLY 3             | P=0.105N | P=0.765N | P=0.743 | P=0.301N |
| POLY 1.5           | P=0.105N | P=0.756N | P=0.715 | P=0.299N |
| POLY 6             | P=0.088N | P=0.784N | P=0.801 | P=0.291N |
| COCH-ARM / FISHERS | P=0.092N | P=0.762N | P=0.714 | P=0.273N |
| MAX-ISO-POLY-3     | P=0.166N | P=0.486N | P=0.460 | P=0.060N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node, Bronchial  
Hyperplasia Lymphoid**

**LESION RATES**

|                    |          |          |          |           |
|--------------------|----------|----------|----------|-----------|
| OVERALL (a)        | 0/3 (0%) | 0/6 (0%) | 0/5 (0%) | 4/8 (50%) |
| POLY-3 RATE (b)    | 0/2.06   | 0/4.42   | 0/3.99   | 4/6.73    |
| POLY-3 PERCENT (g) | 0%       | 0%       | 0%       | 59.4%     |
| TERMINAL (d)       | 0/0 (0%) | 0/0 (0%) | 0/1 (0%) | 1/2 (50%) |
| FIRST INCIDENCE    | ---      | ---      | ---      | 422       |

**STATISTICAL TESTS**

|                    |           |     |     |         |
|--------------------|-----------|-----|-----|---------|
| POLY 3             | P=0.003** | (e) | (e) | P=0.239 |
| POLY 1.5           | P=0.003** | (e) | (e) | P=0.206 |
| POLY 6             | P=0.005** | (e) | (e) | P=0.334 |
| COCH-ARM / FISHERS | P=0.010** | (e) | (e) | P=0.212 |
| MAX-ISO-POLY-3     | P=0.005** | (e) | (e) | P=0.114 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node, Mediastinal  
Angiectasis**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/30 (0%) | 0/25 (0%) | 1/23 (4%) | 3/32 (9%) |
| POLY-3 RATE (b)    | 0/26.46   | 0/19.21   | 1/16.93   | 3/22.12   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 5.9%      | 13.6%     |
| TERMINAL (d)       | 0/17 (0%) | 0/13 (0%) | 0/6 (0%)  | 1/6 (17%) |
| FIRST INCIDENCE    | ---       | ---       | 418       | 562       |

**STATISTICAL TESTS**

|                    |          |     |         |          |
|--------------------|----------|-----|---------|----------|
| POLY 3             | P=0.018* | (e) | P=0.412 | P=0.085  |
| POLY 1.5           | P=0.023* | (e) | P=0.427 | P=0.102  |
| POLY 6             | P=0.013* | (e) | P=0.391 | P=0.067  |
| COCH-ARM / FISHERS | P=0.030* | (e) | P=0.434 | P=0.131  |
| MAX-ISO-POLY-3     | P=0.028* | (e) | P=0.139 | P=0.036* |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node, Mediastinal Hemorrhage**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/30 (0%) | 0/25 (0%) | 0/23 (0%) | 0/32 (0%) |
| POLY-3 RATE (b)    | 0/26.46   | 0/19.21   | 0/16.11   | 0/21.51   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 0%        |
| TERMINAL (d)       | 0/17 (0%) | 0/13 (0%) | 0/6 (0%)  | 0/6 (0%)  |
| FIRST INCIDENCE    | ---       | ---       | ---       | ---       |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node, Mediastinal  
Hyperplasia Lymphoid**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/30 (0%) | 1/25 (4%) | 1/23 (4%) | 2/32 (6%) |
| POLY-3 RATE (b)    | 0/26.46   | 1/19.21   | 1/16.76   | 2/22.50   |
| POLY-3 PERCENT (g) | 0%        | 5.2%      | 6%        | 8.9%      |
| TERMINAL (d)       | 0/17 (0%) | 1/13 (8%) | 0/6 (0%)  | 0/6 (0%)  |
| FIRST INCIDENCE    | ---       | 729 (T)   | 514       | 500       |

**STATISTICAL TESTS**

|                    |         |         |         |         |
|--------------------|---------|---------|---------|---------|
| POLY 3             | P=0.129 | P=0.436 | P=0.410 | P=0.201 |
| POLY 1.5           | P=0.152 | P=0.446 | P=0.426 | P=0.221 |
| POLY 6             | P=0.101 | P=0.427 | P=0.389 | P=0.175 |
| COCH-ARM / FISHERS | P=0.184 | P=0.455 | P=0.434 | P=0.262 |
| MAX-ISO-POLY-3     | P=0.143 | P=0.145 | P=0.139 | P=0.076 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Lymph Node, Mesenteric  
Angiectasis**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 1/50 (2%) | 1/50 (2%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 0/41.44   | 1/40.69   | 1/37.74   | 2/36.10   |
| POLY-3 PERCENT (g) | 0%        | 2.5%      | 2.7%      | 5.5%      |
| TERMINAL (d)       | 0/23 (0%) | 1/26 (4%) | 1/18 (6%) | 0/13 (0%) |
| FIRST INCIDENCE    | ---       | 729 (T)   | 729 (T)   | 653       |

**STATISTICAL TESTS**

|                    |         |         |         |         |
|--------------------|---------|---------|---------|---------|
| POLY 3             | P=0.123 | P=0.496 | P=0.481 | P=0.207 |
| POLY 1.5           | P=0.136 | P=0.497 | P=0.489 | P=0.219 |
| POLY 6             | P=0.109 | P=0.497 | P=0.471 | P=0.192 |
| COCH-ARM / FISHERS | P=0.153 | P=0.500 | P=0.500 | P=0.247 |
| MAX-ISO-POLY-3     | P=0.120 | P=0.158 | P=0.158 | P=0.075 |



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node: Pancreatic  
Angiectasis**

**LESION RATES**

|                    |          |            |          |          |
|--------------------|----------|------------|----------|----------|
| OVERALL (a)        | 0/5 (0%) | 2/5 (40%)  | 0/5 (0%) | 0/4 (0%) |
| POLY-3 RATE (b)    | 0/3.36   | 2/3.82     | 0/3.29   | 0/3.40   |
| POLY-3 PERCENT (g) | 0%       | 52.3%      | 0%       | 0%       |
| TERMINAL (d)       | 0/1 (0%) | 2/2 (100%) | 0/0 (0%) | 0/2 (0%) |
| FIRST INCIDENCE    | ---      | 729 (T)    | ---      | ---      |

**STATISTICAL TESTS**

|                    |          |         |     |     |
|--------------------|----------|---------|-----|-----|
| POLY 3             | P=0.373N | P=0.217 | (e) | (e) |
| POLY 1.5           | P=0.408N | P=0.210 | (e) | (e) |
| POLY 6             | P=0.305N | P=0.246 | (e) | (e) |
| COCH-ARM / FISHERS | P=0.445N | P=0.222 | (e) | (e) |
| MAX-ISO-POLY-3     | P=0.218N | P=0.056 | (e) | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Mammary Gland  
Galactocele**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/40 (3%) | 1/36 (3%) | 0/39 (0%) | 0/36 (0%) |
| POLY-3 RATE (b)    | 1/33.39   | 1/30.32   | 0/28.95   | 0/27.87   |
| POLY-3 PERCENT (g) | 3%        | 3.3%      | 0%        | 0%        |
| TERMINAL (d)       | 0/17 (0%) | 1/19 (5%) | 0/13 (0%) | 0/12 (0%) |
| FIRST INCIDENCE    | 716       | 729 (T)   | ---       | ---       |

**STATISTICAL TESTS**

|                    |          |         |          |          |
|--------------------|----------|---------|----------|----------|
| POLY 3             | P=0.260N | P=0.740 | P=0.528N | P=0.536N |
| POLY 1.5           | P=0.254N | P=0.738 | P=0.519N | P=0.530N |
| POLY 6             | P=0.267N | P=0.744 | P=0.541N | P=0.544N |
| COCH-ARM / FISHERS | P=0.247N | P=0.726 | P=0.506N | P=0.526N |
| MAX-ISO-POLY-3     | P=0.297N | P=0.472 | P=0.191N | P=0.196N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Mesentery  
Necrosis**

**LESION RATES**

|                    |              |              |            |             |
|--------------------|--------------|--------------|------------|-------------|
| OVERALL (a)        | 13/13 (100%) | 13/13 (100%) | 7/8 (88%)  | 17/19 (89%) |
| POLY-3 RATE (b)    | 13/13.00     | 13/13.00     | 7/7.98     | 17/18.37    |
| POLY-3 PERCENT (g) | 100%         | 100%         | 87.7%      | 92.6%       |
| TERMINAL (d)       | 8/8 (100%)   | 6/6 (100%)   | 3/3 (100%) | 3/3 (100%)  |
| FIRST INCIDENCE    | 591          | 611          | 488        | 394         |

**STATISTICAL TESTS**

|                    |          |     |          |          |
|--------------------|----------|-----|----------|----------|
| POLY 3             | P=0.201N | (e) | P=0.408N | P=0.445N |
| POLY 1.5           | P=0.165N | (e) | P=0.405N | P=0.377N |
| POLY 6             | P=0.290N | (e) | P=0.415N | P=0.624N |
| COCH-ARM / FISHERS | P=0.133N | (e) | P=0.381N | P=0.345N |
| MAX-ISO-POLY-3     | P=0.179N | (e) | P=0.122N | P=0.133N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

Nose  
Foreign Body

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 11/50 (22%) | 10/48 (21%) | 15/48 (31%) | 11/50 (22%) |
| POLY-3 RATE (b)    | 11/43.27    | 10/41.18    | 15/39.94    | 11/37.24    |
| POLY-3 PERCENT (g) | 25.4%       | 24.3%       | 37.6%       | 29.5%       |
| TERMINAL (d)       | 5/23 (22%)  | 5/26 (19%)  | 7/18 (39%)  | 3/13 (23%)  |
| FIRST INCIDENCE    | 501         | 505         | 418         | 611         |

**STATISTICAL TESTS**

|                    |         |          |         |          |
|--------------------|---------|----------|---------|----------|
| POLY 3             | P=0.280 | P=0.552N | P=0.165 | P=0.435  |
| POLY 1.5           | P=0.357 | P=0.548N | P=0.184 | P=0.502  |
| POLY 6             | P=0.198 | P=0.553N | P=0.143 | P=0.356  |
| COCH-ARM / FISHERS | P=0.477 | P=0.542N | P=0.210 | P=0.595N |
| MAX-ISO-POLY-3     | P=0.337 | P=0.451N | P=0.118 | P=0.348  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Nose  
Inflammation Chronic**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 29/50 (58%) | 34/48 (71%) | 36/48 (75%) | 42/50 (84%) |
| POLY-3 RATE (b)    | 29/44.85    | 34/43.76    | 36/43.38    | 42/48.57    |
| POLY-3 PERCENT (g) | 64.7%       | 77.7%       | 83%         | 86.5%       |
| TERMINAL (d)       | 16/23 (70%) | 21/26 (81%) | 16/18 (89%) | 9/13 (69%)  |
| FIRST INCIDENCE    | 501         | 505         | 418         | 394         |

**STATISTICAL TESTS**

|                    |           |         |          |           |
|--------------------|-----------|---------|----------|-----------|
| POLY 3             | P=0.006** | P=0.114 | P=0.029* | P=0.008** |
| POLY 1.5           | P=0.004** | P=0.121 | P=0.040* | P=0.005** |
| POLY 6             | P=0.013*  | P=0.114 | P=0.020* | P=0.017*  |
| COCH-ARM / FISHERS | P=0.003** | P=0.132 | P=0.058  | P=0.004** |
| MAX-ISO-POLY-3     | P=0.005** | P=0.072 | P=0.016* | P=0.005** |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Nose: Epithelium  
Accumulation, Hyaline Droplet**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 44/50 (88%) | 39/48 (81%) | 36/48 (75%) | 44/50 (88%) |
| POLY-3 RATE (b)    | 44/48.40    | 39/45.97    | 36/44.55    | 44/48.65    |
| POLY-3 PERCENT (g) | 90.9%       | 84.8%       | 80.8%       | 90.4%       |
| TERMINAL (d)       | 20/23 (87%) | 22/26 (85%) | 14/18 (78%) | 12/13 (92%) |
| FIRST INCIDENCE    | 501         | 505         | 488         | 394         |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.529  | P=0.265N | P=0.116N | P=0.613N |
| POLY 1.5           | P=0.526  | P=0.255N | P=0.094N | P=0.606N |
| POLY 6             | P=0.507  | P=0.294N | P=0.162N | P=0.655N |
| COCH-ARM / FISHERS | P=0.504  | P=0.259N | P=0.080N | P=0.620N |
| MAX-ISO-POLY-3     | P=0.317N | P=0.172N | P=0.070N | P=0.465N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Nose: Glands  
Hyperplasia**

**LESION RATES**

|                    |            |             |             |             |
|--------------------|------------|-------------|-------------|-------------|
| OVERALL (a)        | 5/50 (10%) | 14/48 (29%) | 14/48 (29%) | 15/50 (30%) |
| POLY-3 RATE (b)    | 5/42.60    | 14/40.59    | 14/38.15    | 15/39.83    |
| POLY-3 PERCENT (g) | 11.7%      | 34.5%       | 36.7%       | 37.7%       |
| TERMINAL (d)       | 2/23 (9%)  | 8/26 (31%)  | 9/18 (50%)  | 5/13 (39%)  |
| FIRST INCIDENCE    | 501        | 660         | 534         | 449         |

**STATISTICAL TESTS**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| POLY 3             | P=0.011*  | P=0.011*  | P=0.006** | P=0.005** |
| POLY 1.5           | P=0.017*  | P=0.012*  | P=0.009** | P=0.006** |
| POLY 6             | P=0.007** | P=0.010** | P=0.004** | P=0.003** |
| COCH-ARM / FISHERS | P=0.031*  | P=0.015*  | P=0.015*  | P=0.011*  |
| MAX-ISO-POLY-3     | P=0.007** | P=0.006** | P=0.004** | P=0.003** |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Nose: Olfactory Epithelium  
Metaplasia Respiratory**

**LESION RATES**

|                    |            |             |             |             |
|--------------------|------------|-------------|-------------|-------------|
| OVERALL (a)        | 7/50 (14%) | 10/48 (21%) | 12/48 (25%) | 12/50 (24%) |
| POLY-3 RATE (b)    | 7/42.30    | 10/41.66    | 12/39.54    | 12/38.89    |
| POLY-3 PERCENT (g) | 16.6%      | 24%         | 30.4%       | 30.9%       |
| TERMINAL (d)       | 3/23 (13%) | 5/26 (19%)  | 5/18 (28%)  | 3/13 (23%)  |
| FIRST INCIDENCE    | 586        | 505         | 418         | 484         |

**STATISTICAL TESTS**

|                    |         |         |         |         |
|--------------------|---------|---------|---------|---------|
| POLY 3             | P=0.080 | P=0.280 | P=0.108 | P=0.100 |
| POLY 1.5           | P=0.102 | P=0.274 | P=0.118 | P=0.119 |
| POLY 6             | P=0.059 | P=0.294 | P=0.097 | P=0.081 |
| COCH-ARM / FISHERS | P=0.144 | P=0.266 | P=0.131 | P=0.154 |
| MAX-ISO-POLY-3     | P=0.120 | P=0.197 | P=0.071 | P=0.068 |

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Nose: Respiratory Epithelium  
Hyperplasia**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 14/50 (28%) | 15/48 (31%) | 20/48 (42%) | 17/50 (34%) |
| POLY-3 RATE (b)    | 14/43.82    | 15/41.94    | 20/41.40    | 17/39.45    |
| POLY-3 PERCENT (g) | 32%         | 35.8%       | 48.3%       | 43.1%       |
| TERMINAL (d)       | 6/23 (26%)  | 7/26 (27%)  | 8/18 (44%)  | 5/13 (39%)  |
| FIRST INCIDENCE    | 501         | 505         | 418         | 484         |

**STATISTICAL TESTS**

|                    |         |         |         |         |
|--------------------|---------|---------|---------|---------|
| POLY 3             | P=0.127 | P=0.442 | P=0.087 | P=0.200 |
| POLY 1.5           | P=0.175 | P=0.444 | P=0.097 | P=0.250 |
| POLY 6             | P=0.082 | P=0.444 | P=0.077 | P=0.148 |
| COCH-ARM / FISHERS | P=0.266 | P=0.448 | P=0.113 | P=0.333 |
| MAX-ISO-POLY-3     | P=0.170 | P=0.353 | P=0.059 | P=0.153 |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Nose: Respiratory Epithelium  
Metaplasia**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 1/48 (2%) | 0/48 (0%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 1/41.70   | 1/39.97   | 0/36.71   | 2/36.17   |
| POLY-3 PERCENT (g) | 2.4%      | 2.5%      | 0%        | 5.5%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | 660       | 663       | ---       | 659       |

**STATISTICAL TESTS**

|                    |         |         |          |         |
|--------------------|---------|---------|----------|---------|
| POLY 3             | P=0.335 | P=0.752 | P=0.525N | P=0.450 |
| POLY 1.5           | P=0.350 | P=0.751 | P=0.518N | P=0.471 |
| POLY 6             | P=0.316 | P=0.754 | P=0.535N | P=0.424 |
| COCH-ARM / FISHERS | P=0.370 | P=0.742 | P=0.510N | P=0.500 |
| MAX-ISO-POLY-3     | P=0.263 | P=0.487 | P=0.187N | P=0.254 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Oral Mucosa  
Foreign Body**

**LESION RATES**

|                    |           |          |           |            |
|--------------------|-----------|----------|-----------|------------|
| OVERALL (a)        | 1/3 (33%) | 0/0 (0%) | 1/2 (50%) | 2/4 (50%)  |
| POLY-3 RATE (b)    | 1/2.77    | 0/0.00   | 1/2.00    | 2/3.52     |
| POLY-3 PERCENT (g) | 36.1%     | 0%       | 50%       | 56.8%      |
| TERMINAL (d)       | 0/1 (0%)  | 0/0 (0%) | 1/2 (50%) | 1/1 (100%) |
| FIRST INCIDENCE    | 724       | ---      | 729 (T)   | 666        |

**STATISTICAL TESTS**

|                    |         |     |         |         |
|--------------------|---------|-----|---------|---------|
| POLY 3             | (e)     | (e) | P=0.694 | P=0.602 |
| POLY 1.5           | (e)     | (e) | P=0.682 | P=0.607 |
| POLY 6             | (e)     | (e) | P=0.714 | P=0.593 |
| COCH-ARM / FISHERS | P=0.483 | (e) | P=0.700 | P=0.629 |
| MAX-ISO-POLY-3     | (e)     | (e) | P=0.407 | P=0.328 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Oral Mucosa  
Hyperplasia**

**LESION RATES**

|                    |            |          |           |          |
|--------------------|------------|----------|-----------|----------|
| OVERALL (a)        | 1/3 (33%)  | 0/0 (0%) | 1/2 (50%) | 0/4 (0%) |
| POLY-3 RATE (b)    | 1/2.75     | 0/0.00   | 1/2.00    | 0/3.29   |
| POLY-3 PERCENT (g) | 36.3%      | 0%       | 50%       | 0%       |
| TERMINAL (d)       | 1/1 (100%) | 0/0 (0%) | 1/2 (50%) | 0/1 (0%) |
| FIRST INCIDENCE    | 729 (T)    | ---      | 729 (T)   | ---      |

**STATISTICAL TESTS**

|                    |          |     |         |          |
|--------------------|----------|-----|---------|----------|
| POLY 3             | (e)      | (e) | P=0.696 | P=0.463N |
| POLY 1.5           | (e)      | (e) | P=0.684 | P=0.452N |
| POLY 6             | (e)      | (e) | P=0.719 | P=0.484N |
| COCH-ARM / FISHERS | P=0.254N | (e) | P=0.700 | P=0.429N |
| MAX-ISO-POLY-3     | (e)      | (e) | P=0.409 | P=0.127N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Oral Mucosa  
Inflammation Chronic**

**LESION RATES**

|                    |           |          |          |            |
|--------------------|-----------|----------|----------|------------|
| OVERALL (a)        | 1/3 (33%) | 0/0 (0%) | 0/2 (0%) | 2/4 (50%)  |
| POLY-3 RATE (b)    | 1/2.77    | 0/0.00   | 0/2.00   | 2/3.52     |
| POLY-3 PERCENT (g) | 36.1%     | 0%       | 0%       | 56.8%      |
| TERMINAL (d)       | 0/1 (0%)  | 0/0 (0%) | 0/2 (0%) | 1/1 (100%) |
| FIRST INCIDENCE    | 724       | ---      | ---      | 666        |

**STATISTICAL TESTS**

|                    |         |     |          |         |
|--------------------|---------|-----|----------|---------|
| POLY 3             | (e)     | (e) | P=0.564N | P=0.602 |
| POLY 1.5           | (e)     | (e) | P=0.570N | P=0.607 |
| POLY 6             | (e)     | (e) | P=0.552N | P=0.593 |
| COCH-ARM / FISHERS | P=0.446 | (e) | P=0.600N | P=0.629 |
| MAX-ISO-POLY-3     | (e)     | (e) | P=0.217N | P=0.328 |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Pancreas: Acinus Atrophy**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 23/50 (46%) | 13/50 (26%) | 20/50 (40%) | 23/50 (46%) |
| POLY-3 RATE (b)    | 23/45.35    | 13/42.41    | 20/43.66    | 23/40.03    |
| POLY-3 PERCENT (g) | 50.7%       | 30.7%       | 45.8%       | 57.5%       |
| TERMINAL (d)       | 10/23 (44%) | 8/26 (31%)  | 7/18 (39%)  | 8/13 (62%)  |
| FIRST INCIDENCE    | 501         | 560         | 418         | 453         |

**STATISTICAL TESTS**

|                    |         |           |          |          |
|--------------------|---------|-----------|----------|----------|
| POLY 3             | P=0.145 | P=0.040N* | P=0.399N | P=0.337  |
| POLY 1.5           | P=0.197 | P=0.035N* | P=0.372N | P=0.437  |
| POLY 6             | P=0.097 | P=0.050N* | P=0.442N | P=0.226  |
| COCH-ARM / FISHERS | P=0.287 | P=0.030N* | P=0.343N | P=0.579N |
| MAX-ISO-POLY-3     | P=0.107 | P=0.028N* | P=0.321N | P=0.271  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Parathyroid Gland  
Hyperplasia**

**LESION RATES**

|                    |            |           |           |           |
|--------------------|------------|-----------|-----------|-----------|
| OVERALL (a)        | 2/46 (4%)  | 0/48 (0%) | 0/47 (0%) | 0/46 (0%) |
| POLY-3 RATE (b)    | 2/37.44    | 0/38.69   | 0/35.30   | 0/34.24   |
| POLY-3 PERCENT (g) | 5.3%       | 0%        | 0%        | 0%        |
| TERMINAL (d)       | 2/19 (11%) | 0/24 (0%) | 0/16 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | 729 (T)    | ---       | ---       | ---       |

**STATISTICAL TESTS**

|                    |           |          |          |          |
|--------------------|-----------|----------|----------|----------|
| POLY 3             | P=0.112N  | P=0.229N | P=0.250N | P=0.257N |
| POLY 1.5           | P=0.112N  | P=0.230N | P=0.242N | P=0.248N |
| POLY 6             | P=0.113N  | P=0.226N | P=0.259N | P=0.268N |
| COCH-ARM / FISHERS | P=0.114N  | P=0.237N | P=0.242N | P=0.247N |
| MAX-ISO-POLY-3     | P=0.047N* | P=0.073N | P=0.089N | P=0.094N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Pituitary Gland  
Cyst**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 2/50 (4%) | 1/50 (2%) | 0/49 (0%) |
| POLY-3 RATE (b)    | 1/41.74   | 2/40.73   | 1/37.74   | 0/35.06   |
| POLY-3 PERCENT (g) | 2.4%      | 4.9%      | 2.7%      | 0%        |
| TERMINAL (d)       | 0/23 (0%) | 1/26 (4%) | 1/18 (6%) | 0/13 (0%) |
| FIRST INCIDENCE    | 646       | 719       | 729 (T)   | ---       |

**STATISTICAL TESTS**

|                    |          |         |          |          |
|--------------------|----------|---------|----------|----------|
| POLY 3             | P=0.295N | P=0.491 | P=0.738  | P=0.535N |
| POLY 1.5           | P=0.276N | P=0.494 | P=0.748  | P=0.522N |
| POLY 6             | P=0.322N | P=0.491 | P=0.724  | P=0.552N |
| COCH-ARM / FISHERS | P=0.251N | P=0.500 | P=0.753N | P=0.505N |
| MAX-ISO-POLY-3     | P=0.290N | P=0.275 | P=0.472  | P=0.199N |

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Pituitary Gland Hemorrhage**

**LESION RATES**

|                    |           |           |            |           |
|--------------------|-----------|-----------|------------|-----------|
| OVERALL (a)        | 4/50 (8%) | 2/50 (4%) | 5/50 (10%) | 0/49 (0%) |
| POLY-3 RATE (b)    | 4/42.64   | 2/41.44   | 5/39.36    | 0/35.06   |
| POLY-3 PERCENT (g) | 9.4%      | 4.8%      | 12.7%      | 0%        |
| TERMINAL (d)       | 1/23 (4%) | 0/26 (0%) | 1/18 (6%)  | 0/13 (0%) |
| FIRST INCIDENCE    | 582       | 505       | 488        | ---       |

**STATISTICAL TESTS**

|                    |          |          |         |           |
|--------------------|----------|----------|---------|-----------|
| POLY 3             | P=0.149N | P=0.350N | P=0.450 | P=0.088N  |
| POLY 1.5           | P=0.125N | P=0.346N | P=0.472 | P=0.077N  |
| POLY 6             | P=0.187N | P=0.352N | P=0.422 | P=0.107N  |
| COCH-ARM / FISHERS | P=0.099N | P=0.339N | P=0.500 | P=0.061N  |
| MAX-ISO-POLY-3     | P=0.109N | P=0.213N | P=0.322 | P=0.043N* |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Pituitary Gland: Pars Distalis  
Hyperplasia**

**LESION RATES**

|                    |            |            |             |            |
|--------------------|------------|------------|-------------|------------|
| OVERALL (a)        | 8/50 (16%) | 5/50 (10%) | 11/50 (22%) | 7/49 (14%) |
| POLY-3 RATE (b)    | 8/42.78    | 5/40.85    | 11/39.83    | 7/36.17    |
| POLY-3 PERCENT (g) | 18.7%      | 12.2%      | 27.6%       | 19.4%      |
| TERMINAL (d)       | 5/23 (22%) | 4/26 (15%) | 6/18 (33%)  | 2/13 (15%) |
| FIRST INCIDENCE    | 429        | 687        | 520         | 642        |

**STATISTICAL TESTS**

|                    |         |          |         |          |
|--------------------|---------|----------|---------|----------|
| POLY 3             | P=0.354 | P=0.303N | P=0.239 | P=0.585  |
| POLY 1.5           | P=0.410 | P=0.295N | P=0.267 | P=0.592N |
| POLY 6             | P=0.291 | P=0.307N | P=0.207 | P=0.531  |
| COCH-ARM / FISHERS | P=0.495 | P=0.277N | P=0.306 | P=0.517N |
| MAX-ISO-POLY-3     | P=0.319 | P=0.212N | P=0.174 | P=0.471  |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Preputial Gland  
Hyperplasia**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 3/50 (6%) | 0/50 (0%) | 0/49 (0%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 3/41.93   | 0/40.69   | 0/37.18   | 1/35.80   |
| POLY-3 PERCENT (g) | 7.2%      | 0%        | 0%        | 2.8%      |
| TERMINAL (d)       | 1/23 (4%) | 0/26 (0%) | 0/18 (0%) | 1/13 (8%) |
| FIRST INCIDENCE    | 660       | ---       | ---       | 729 (T)   |

**STATISTICAL TESTS**

|                    |          |           |          |          |
|--------------------|----------|-----------|----------|----------|
| POLY 3             | P=0.247N | P=0.123N  | P=0.141N | P=0.363N |
| POLY 1.5           | P=0.247N | P=0.122N  | P=0.133N | P=0.338N |
| POLY 6             | P=0.249N | P=0.124N  | P=0.153N | P=0.399N |
| COCH-ARM / FISHERS | P=0.248N | P=0.121N  | P=0.125N | P=0.309N |
| MAX-ISO-POLY-3     | P=0.082N | P=0.042N* | P=0.056N | P=0.212N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Preputial Gland  
Inflammation Chronic**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 30/50 (60%) | 34/50 (68%) | 31/49 (63%) | 37/50 (74%) |
| POLY-3 RATE (b)    | 30/45.82    | 34/43.95    | 31/41.43    | 37/44.04    |
| POLY-3 PERCENT (g) | 65.5%       | 77.4%       | 74.8%       | 84%         |
| TERMINAL (d)       | 15/23 (65%) | 24/26 (92%) | 16/18 (89%) | 12/13 (92%) |
| FIRST INCIDENCE    | 582         | 505         | 514         | 453         |

**STATISTICAL TESTS**

|                    |          |         |         |          |
|--------------------|----------|---------|---------|----------|
| POLY 3             | P=0.025* | P=0.138 | P=0.220 | P=0.026* |
| POLY 1.5           | P=0.049* | P=0.188 | P=0.319 | P=0.045* |
| POLY 6             | P=0.011* | P=0.084 | P=0.114 | P=0.014* |
| COCH-ARM / FISHERS | P=0.109  | P=0.266 | P=0.449 | P=0.101  |
| MAX-ISO-POLY-3     | P=0.019* | P=0.095 | P=0.164 | P=0.015* |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Prostate  
Hyperplasia**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 12/50 (24%) | 13/50 (26%) | 10/50 (20%) | 17/50 (34%) |
| POLY-3 RATE (b)    | 12/42.52    | 13/42.65    | 10/38.98    | 17/38.32    |
| POLY-3 PERCENT (g) | 28.2%       | 30.5%       | 25.7%       | 44.4%       |
| TERMINAL (d)       | 8/23 (35%)  | 7/26 (27%)  | 5/18 (28%)  | 8/13 (62%)  |
| FIRST INCIDENCE    | 596         | 569         | 603         | 422         |

**STATISTICAL TESTS**

|                    |          |         |          |         |
|--------------------|----------|---------|----------|---------|
| POLY 3             | P=0.078  | P=0.504 | P=0.495N | P=0.093 |
| POLY 1.5           | P=0.110  | P=0.497 | P=0.456N | P=0.129 |
| POLY 6             | P=0.047* | P=0.527 | P=0.546N | P=0.057 |
| COCH-ARM / FISHERS | P=0.163  | P=0.500 | P=0.405N | P=0.189 |
| MAX-ISO-POLY-3     | P=0.101  | P=0.407 | P=0.398N | P=0.068 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Prostate  
Inflammation**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 38/50 (76%) | 42/50 (84%) | 40/50 (80%) | 36/50 (72%) |
| POLY-3 RATE (b)    | 38/46.21    | 42/47.70    | 40/45.55    | 36/44.26    |
| POLY-3 PERCENT (g) | 82.2%       | 88%         | 87.8%       | 81.3%       |
| TERMINAL (d)       | 20/23 (87%) | 22/26 (85%) | 16/18 (89%) | 11/13 (85%) |
| FIRST INCIDENCE    | 534         | 505         | 514         | 394         |

**STATISTICAL TESTS**

|                    |          |         |         |          |
|--------------------|----------|---------|---------|----------|
| POLY 3             | P=0.429N | P=0.293 | P=0.303 | P=0.572N |
| POLY 1.5           | P=0.333N | P=0.247 | P=0.342 | P=0.496N |
| POLY 6             | P=0.562  | P=0.397 | P=0.281 | P=0.608  |
| COCH-ARM / FISHERS | P=0.244N | P=0.227 | P=0.405 | P=0.410N |
| MAX-ISO-POLY-3     | P=0.400N | P=0.199 | P=0.201 | P=0.450N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Salivary Glands  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 1/50 (2%) | 3/50 (6%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 0/41.44   | 1/41.36   | 3/38.44   | 2/37.06   |
| POLY-3 PERCENT (g) | 0%        | 2.4%      | 7.8%      | 5.4%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 1/18 (6%) | 0/13 (0%) |
| FIRST INCIDENCE    | ---       | 505       | 603       | 449       |

**STATISTICAL TESTS**

|                    |         |         |          |         |
|--------------------|---------|---------|----------|---------|
| POLY 3             | P=0.125 | P=0.500 | P=0.105  | P=0.213 |
| POLY 1.5           | P=0.140 | P=0.499 | P=0.111  | P=0.223 |
| POLY 6             | P=0.106 | P=0.502 | P=0.098  | P=0.200 |
| COCH-ARM / FISHERS | P=0.163 | P=0.500 | P=0.121  | P=0.247 |
| MAX-ISO-POLY-3     | P=0.116 | P=0.158 | P=0.037* | P=0.075 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Seminal Vesicle  
Inflammation**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 2/50 (4%) | 1/49 (2%) | 0/49 (0%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 2/41.80   | 1/40.13   | 0/36.86   | 2/35.98   |
| POLY-3 PERCENT (g) | 4.8%      | 2.5%      | 0%        | 5.6%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 1/13 (8%) |
| FIRST INCIDENCE    | 635       | 711       | ---       | 682       |

**STATISTICAL TESTS**

|                    |         |          |          |          |
|--------------------|---------|----------|----------|----------|
| POLY 3             | P=0.555 | P=0.514N | P=0.266N | P=0.639  |
| POLY 1.5           | P=0.571 | P=0.513N | P=0.255N | P=0.663  |
| POLY 6             | P=0.533 | P=0.513N | P=0.280N | P=0.608  |
| COCH-ARM / FISHERS | P=0.592 | P=0.508N | P=0.253N | P=0.691N |
| MAX-ISO-POLY-3     | P=0.393 | P=0.295N | P=0.102N | P=0.442  |



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Skin  
Hyperkeratosis**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 3/50 (6%) | 0/50 (0%) | 2/50 (4%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 3/41.70   | 0/40.69   | 2/38.01   | 0/35.80   |
| POLY-3 PERCENT (g) | 7.2%      | 0%        | 5.3%      | 0%        |
| TERMINAL (d)       | 2/23 (9%) | 0/26 (0%) | 1/18 (6%) | 0/13 (0%) |
| FIRST INCIDENCE    | 660       | ---       | 658       | ---       |

**STATISTICAL TESTS**

|                    |          |           |          |          |
|--------------------|----------|-----------|----------|----------|
| POLY 3             | P=0.145N | P=0.122N  | P=0.542N | P=0.148N |
| POLY 1.5           | P=0.135N | P=0.122N  | P=0.524N | P=0.135N |
| POLY 6             | P=0.158N | P=0.122N  | P=0.566N | P=0.166N |
| COCH-ARM / FISHERS | P=0.125N | P=0.121N  | P=0.500N | P=0.121N |
| MAX-ISO-POLY-3     | P=0.074N | P=0.041N* | P=0.367N | P=0.063N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Skin  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |            |             |
|--------------------|-----------|-----------|------------|-------------|
| OVERALL (a)        | 1/50 (2%) | 4/50 (8%) | 5/50 (10%) | 14/50 (28%) |
| POLY-3 RATE (b)    | 1/41.44   | 4/41.17   | 5/39.66    | 14/41.01    |
| POLY-3 PERCENT (g) | 2.4%      | 9.7%      | 12.6%      | 34.1%       |
| TERMINAL (d)       | 1/23 (4%) | 2/26 (8%) | 2/18 (11%) | 1/13 (8%)   |
| FIRST INCIDENCE    | 729 (T)   | 611       | 418        | 422         |

**STATISTICAL TESTS**

|                    |           |         |          |           |
|--------------------|-----------|---------|----------|-----------|
| POLY 3             | P<0.001** | P=0.175 | P=0.090  | P<0.001** |
| POLY 1.5           | P<0.001** | P=0.176 | P=0.095  | P<0.001** |
| POLY 6             | P<0.001** | P=0.179 | P=0.083  | P<0.001** |
| COCH-ARM / FISHERS | P<0.001** | P=0.181 | P=0.102  | P<0.001** |
| MAX-ISO-POLY-3     | P<0.001** | P=0.082 | P=0.041* | P<0.001** |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Spleen  
Fibrosis**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 2/50 (4%) | 1/49 (2%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 1/41.44   | 2/40.69   | 1/37.29   | 0/35.80   |
| POLY-3 PERCENT (g) | 2.4%      | 4.9%      | 2.7%      | 0%        |
| TERMINAL (d)       | 1/23 (4%) | 2/26 (8%) | 1/18 (6%) | 0/13 (0%) |
| FIRST INCIDENCE    | 729 (T)   | 729 (T)   | 729 (T)   | ---       |

**STATISTICAL TESTS**

|                    |          |         |         |          |
|--------------------|----------|---------|---------|----------|
| POLY 3             | P=0.289N | P=0.494 | P=0.737 | P=0.529N |
| POLY 1.5           | P=0.272N | P=0.495 | P=0.745 | P=0.517N |
| POLY 6             | P=0.313N | P=0.495 | P=0.726 | P=0.545N |
| COCH-ARM / FISHERS | P=0.248N | P=0.500 | P=0.747 | P=0.500N |
| MAX-ISO-POLY-3     | P=0.284N | P=0.276 | P=0.470 | P=0.193N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Spleen  
Hematopoietic Cell Proliferation**

**LESION RATES**

|                    |             |             |             |            |
|--------------------|-------------|-------------|-------------|------------|
| OVERALL (a)        | 10/50 (20%) | 17/50 (34%) | 13/49 (27%) | 6/50 (12%) |
| POLY-3 RATE (b)    | 10/42.00    | 17/41.26    | 13/37.99    | 6/36.17    |
| POLY-3 PERCENT (g) | 23.8%       | 41.2%       | 34.2%       | 16.6%      |
| TERMINAL (d)       | 7/23 (30%)  | 15/26 (58%) | 8/18 (44%)  | 4/13 (31%) |
| FIRST INCIDENCE    | 660         | 585         | 682         | 659        |

**STATISTICAL TESTS**

|                    |          |          |         |          |
|--------------------|----------|----------|---------|----------|
| POLY 3             | P=0.169N | P=0.066  | P=0.213 | P=0.305N |
| POLY 1.5           | P=0.122N | P=0.073  | P=0.249 | P=0.260N |
| POLY 6             | P=0.251N | P=0.060  | P=0.173 | P=0.370N |
| COCH-ARM / FISHERS | P=0.079N | P=0.088  | P=0.298 | P=0.207N |
| MAX-ISO-POLY-3     | P=0.100N | P=0.041* | P=0.158 | P=0.230N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Spleen  
Hemorrhage Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 4/50 (8%) | 0/50 (0%) | 1/49 (2%) | 3/50 (6%) |
| POLY-3 RATE (b)    | 4/42.73   | 0/40.69   | 1/37.37   | 3/36.53   |
| POLY-3 PERCENT (g) | 9.4%      | 0%        | 2.7%      | 8.2%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | 591       | ---       | 709       | 639       |

**STATISTICAL TESTS**

|                    |          |           |          |          |
|--------------------|----------|-----------|----------|----------|
| POLY 3             | P=0.561  | P=0.066N  | P=0.221N | P=0.585N |
| POLY 1.5           | P=0.576  | P=0.064N  | P=0.205N | P=0.550N |
| POLY 6             | P=0.539  | P=0.068N  | P=0.245N | P=0.631N |
| COCH-ARM / FISHERS | P=0.595  | P=0.059N  | P=0.187N | P=0.500N |
| MAX-ISO-POLY-3     | P=0.216N | P=0.024N* | P=0.123N | P=0.432N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Spleen  
Infarct Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 1/50 (2%) | 2/49 (4%) | 3/50 (6%) |
| POLY-3 RATE (b)    | 0/41.44   | 1/41.23   | 2/37.37   | 3/36.24   |
| POLY-3 PERCENT (g) | 0%        | 2.4%      | 5.4%      | 8.3%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 1/18 (6%) | 1/13 (8%) |
| FIRST INCIDENCE    | ---       | 562       | 709       | 639       |

**STATISTICAL TESTS**

|                    |          |         |         |          |
|--------------------|----------|---------|---------|----------|
| POLY 3             | P=0.043* | P=0.499 | P=0.214 | P=0.096  |
| POLY 1.5           | P=0.051  | P=0.499 | P=0.222 | P=0.105  |
| POLY 6             | P=0.036* | P=0.502 | P=0.204 | P=0.085  |
| COCH-ARM / FISHERS | P=0.062  | P=0.500 | P=0.242 | P=0.121  |
| MAX-ISO-POLY-3     | P=0.060  | P=0.158 | P=0.074 | P=0.037* |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Spleen  
Inflammation Granulomatous**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/49 (0%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 0/41.44   | 0/40.69   | 0/37.29   | 0/35.80   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 0%        |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | ---       |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Stomach, Forestomach  
Hyperplasia**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 1/50 (2%) | 1/50 (2%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 1/41.91   | 1/41.23   | 1/37.87   | 1/36.08   |
| POLY-3 PERCENT (g) | 2.4%      | 2.4%      | 2.6%      | 2.8%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | 591       | 562       | 697       | 653       |

**STATISTICAL TESTS**

|                    |         |          |          |          |
|--------------------|---------|----------|----------|----------|
| POLY 3             | P=0.579 | P=0.757  | P=0.738  | P=0.727  |
| POLY 1.5           | P=0.602 | P=0.758  | P=0.748  | P=0.741  |
| POLY 6             | P=0.548 | P=0.759  | P=0.725  | P=0.707  |
| COCH-ARM / FISHERS | P=0.634 | P=0.753N | P=0.753N | P=0.753N |
| MAX-ISO-POLY-3     | P=0.702 | P=0.495  | P=0.471  | P=0.460  |

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Stomach, Forestomach  
Ulcer**

**LESION RATES**

|                    |            |           |            |           |
|--------------------|------------|-----------|------------|-----------|
| OVERALL (a)        | 7/50 (14%) | 3/50 (6%) | 5/50 (10%) | 4/50 (8%) |
| POLY-3 RATE (b)    | 7/43.36    | 3/41.95   | 5/39.06    | 4/37.18   |
| POLY-3 PERCENT (g) | 16.1%      | 7.2%      | 12.8%      | 10.8%     |
| TERMINAL (d)       | 1/23 (4%)  | 0/26 (0%) | 0/18 (0%)  | 1/13 (8%) |
| FIRST INCIDENCE    | 582        | 585       | 603        | 446       |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.379N | P=0.169N | P=0.454N | P=0.354N |
| POLY 1.5           | P=0.343N | P=0.166N | P=0.421N | P=0.313N |
| POLY 6             | P=0.433N | P=0.171N | P=0.496N | P=0.415N |
| COCH-ARM / FISHERS | P=0.298N | P=0.159N | P=0.380N | P=0.262N |
| MAX-ISO-POLY-3     | P=0.357N | P=0.101N | P=0.341N | P=0.258N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Stomach, Glandular  
Ulcer**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 2/50 (4%) | 1/50 (2%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 1/41.74   | 2/41.58   | 1/37.87   | 0/35.80   |
| POLY-3 PERCENT (g) | 2.4%      | 4.8%      | 2.6%      | 0%        |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | 646       | 585       | 697       | ---       |

**STATISTICAL TESTS**

|                    |          |         |          |          |
|--------------------|----------|---------|----------|----------|
| POLY 3             | P=0.291N | P=0.499 | P=0.739  | P=0.531N |
| POLY 1.5           | P=0.272N | P=0.498 | P=0.748  | P=0.518N |
| POLY 6             | P=0.318N | P=0.504 | P=0.726  | P=0.548N |
| COCH-ARM / FISHERS | P=0.247N | P=0.500 | P=0.753N | P=0.500N |
| MAX-ISO-POLY-3     | P=0.289N | P=0.279 | P=0.472  | P=0.196N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

Testes: Germinal Epithelium Atrophy

**LESION RATES**

|                    |             |            |            |            |
|--------------------|-------------|------------|------------|------------|
| OVERALL (a)        | 12/50 (24%) | 8/50 (16%) | 7/50 (14%) | 6/50 (12%) |
| POLY-3 RATE (b)    | 12/42.59    | 8/40.73    | 7/38.71    | 6/36.39    |
| POLY-3 PERCENT (g) | 28.2%       | 19.6%      | 18.1%      | 16.5%      |
| TERMINAL (d)       | 7/23 (30%)  | 7/26 (27%) | 5/18 (28%) | 4/13 (31%) |
| FIRST INCIDENCE    | 646         | 719        | 488        | 639        |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.134N | P=0.254N | P=0.206N | P=0.165N |
| POLY 1.5           | P=0.110N | P=0.244N | P=0.181N | P=0.131N |
| POLY 6             | P=0.177N | P=0.266N | P=0.248N | P=0.219N |
| COCH-ARM / FISHERS | P=0.083N | P=0.227N | P=0.154N | P=0.096N |
| MAX-ISO-POLY-3     | P=0.185N | P=0.184N | P=0.149N | P=0.123N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

Testes: Interstitial Cell  
Hyperplasia

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 0/50 (0%) | 2/50 (4%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 1/41.92   | 0/40.69   | 2/38.89   | 1/36.08   |
| POLY-3 PERCENT (g) | 2.4%      | 0%        | 5.1%      | 2.8%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | 586       | ---       | 536       | 653       |

**STATISTICAL TESTS**

|                    |         |          |         |          |
|--------------------|---------|----------|---------|----------|
| POLY 3             | P=0.440 | P=0.506N | P=0.474 | P=0.727  |
| POLY 1.5           | P=0.465 | P=0.504N | P=0.485 | P=0.741  |
| POLY 6             | P=0.406 | P=0.507N | P=0.459 | P=0.707  |
| COCH-ARM / FISHERS | P=0.500 | P=0.500N | P=0.500 | P=0.753N |
| MAX-ISO-POLY-3     | P=0.382 | P=0.166N | P=0.265 | P=0.459  |

---

TDMS No. 20011 - 05  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 1-Bromopropane  
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008  
 Time Report Requested: 10:20:06  
 First Dose M/F: 07/14/03 / 07/14/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Thyroid Gland: C-Cell  
 Hyperplasia**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 32/50 (64%) | 31/50 (62%) | 29/50 (58%) | 34/49 (69%) |
| POLY-3 RATE (b)    | 32/46.15    | 31/43.77    | 29/41.73    | 34/42.99    |
| POLY-3 PERCENT (g) | 69.3%       | 70.8%       | 69.5%       | 79.1%       |
| TERMINAL (d)       | 15/23 (65%) | 21/26 (81%) | 14/18 (78%) | 10/13 (77%) |
| FIRST INCIDENCE    | 534         | 540         | 536         | 422         |

**STATISTICAL TESTS**

|                    |         |          |          |         |
|--------------------|---------|----------|----------|---------|
| POLY 3             | P=0.156 | P=0.532  | P=0.591  | P=0.193 |
| POLY 1.5           | P=0.216 | P=0.589  | P=0.481N | P=0.256 |
| POLY 6             | P=0.104 | P=0.450  | P=0.438  | P=0.138 |
| COCH-ARM / FISHERS | P=0.312 | P=0.500N | P=0.341N | P=0.361 |
| MAX-ISO-POLY-3     | P=0.219 | P=0.435  | P=0.492  | P=0.136 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Thyroid Gland: Follicular Cell  
Hyperplasia**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 1/50 (2%) | 0/50 (0%) | 0/49 (0%) |
| POLY-3 RATE (b)    | 0/41.44   | 1/40.77   | 0/37.74   | 0/35.42   |
| POLY-3 PERCENT (g) | 0%        | 2.5%      | 0%        | 0%        |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | ---       | 708       | ---       | ---       |

**STATISTICAL TESTS**

|                    |          |         |     |     |
|--------------------|----------|---------|-----|-----|
| POLY 3             | P=0.585N | P=0.497 | (e) | (e) |
| POLY 1.5           | P=0.579N | P=0.497 | (e) | (e) |
| POLY 6             | P=0.593N | P=0.498 | (e) | (e) |
| COCH-ARM / FISHERS | P=0.571N | P=0.500 | (e) | (e) |
| MAX-ISO-POLY-3     | P=0.433N | P=0.158 | (e) | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Trachea  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 1/50 (2%) | 1/50 (2%) | 4/50 (8%) |
| POLY-3 RATE (b)    | 1/41.70   | 1/40.76   | 1/37.89   | 4/38.63   |
| POLY-3 PERCENT (g) | 2.4%      | 2.5%      | 2.6%      | 10.4%     |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | 660       | 711       | 690       | 394       |

**STATISTICAL TESTS**

|                    |         |          |          |         |
|--------------------|---------|----------|----------|---------|
| POLY 3             | P=0.057 | P=0.756  | P=0.739  | P=0.155 |
| POLY 1.5           | P=0.062 | P=0.757  | P=0.749  | P=0.165 |
| POLY 6             | P=0.051 | P=0.757  | P=0.727  | P=0.140 |
| COCH-ARM / FISHERS | P=0.067 | P=0.753N | P=0.753N | P=0.181 |
| MAX-ISO-POLY-3     | P=0.071 | P=0.493  | P=0.473  | P=0.077 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males   |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Trachea: Epithelium  
Hyperplasia**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 0/50 (0%) | 0/50 (0%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 1/41.70   | 0/40.69   | 0/37.74   | 1/36.34   |
| POLY-3 PERCENT (g) | 2.4%      | 0%        | 0%        | 2.8%      |
| TERMINAL (d)       | 0/23 (0%) | 0/26 (0%) | 0/18 (0%) | 0/13 (0%) |
| FIRST INCIDENCE    | 660       | ---       | ---       | 562       |

**STATISTICAL TESTS**

|                    |         |          |          |          |
|--------------------|---------|----------|----------|----------|
| POLY 3             | P=0.575 | P=0.505N | P=0.520N | P=0.730  |
| POLY 1.5           | P=0.583 | P=0.503N | P=0.511N | P=0.743  |
| POLY 6             | P=0.562 | P=0.505N | P=0.532N | P=0.711  |
| COCH-ARM / FISHERS | P=0.595 | P=0.500N | P=0.500N | P=0.753N |
| MAX-ISO-POLY-3     | P=0.391 | P=0.164N | P=0.182N | P=0.463  |



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Adrenal Cortex  
Hyperplasia**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 27/50 (54%) | 30/50 (60%) | 24/50 (48%) | 26/50 (52%) |
| POLY-3 RATE (b)    | 27/47.14    | 30/45.27    | 24/43.49    | 26/40.20    |
| POLY-3 PERCENT (g) | 57.3%       | 66.3%       | 55.2%       | 64.7%       |
| TERMINAL (d)       | 22/34 (65%) | 24/33 (73%) | 20/30 (67%) | 18/24 (75%) |
| FIRST INCIDENCE    | 493         | 577         | 607         | 450         |

**STATISTICAL TESTS**

|                    |          |         |          |          |
|--------------------|----------|---------|----------|----------|
| POLY 3             | P=0.374  | P=0.243 | P=0.505N | P=0.308  |
| POLY 1.5           | P=0.492  | P=0.282 | P=0.436N | P=0.418  |
| POLY 6             | P=0.255  | P=0.208 | P=0.589  | P=0.206  |
| COCH-ARM / FISHERS | P=0.342N | P=0.343 | P=0.345N | P=0.500N |
| MAX-ISO-POLY-3     | P=0.402  | P=0.185 | P=0.420N | P=0.250  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Adrenal Cortex  
Vacuolization Cytoplasmic**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 12/50 (24%) | 16/50 (32%) | 16/50 (32%) | 11/50 (22%) |
| POLY-3 RATE (b)    | 12/45.61    | 16/43.86    | 16/43.81    | 11/39.02    |
| POLY-3 PERCENT (g) | 26.3%       | 36.5%       | 36.5%       | 28.2%       |
| TERMINAL (d)       | 10/34 (29%) | 15/33 (46%) | 11/30 (37%) | 8/24 (33%)  |
| FIRST INCIDENCE    | 683         | 708         | 607         | 578         |

**STATISTICAL TESTS**

|                    |          |         |         |          |
|--------------------|----------|---------|---------|----------|
| POLY 3             | P=0.505  | P=0.207 | P=0.206 | P=0.520  |
| POLY 1.5           | P=0.512N | P=0.226 | P=0.224 | P=0.571  |
| POLY 6             | P=0.439  | P=0.186 | P=0.191 | P=0.468  |
| COCH-ARM / FISHERS | P=0.364N | P=0.252 | P=0.252 | P=0.500N |
| MAX-ISO-POLY-3     | P=0.393  | P=0.152 | P=0.151 | P=0.427  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Adrenal Medulla  
Hyperplasia**

**LESION RATES**

|                    |            |            |            |            |
|--------------------|------------|------------|------------|------------|
| OVERALL (a)        | 4/50 (8%)  | 9/50 (18%) | 7/50 (14%) | 6/50 (12%) |
| POLY-3 RATE (b)    | 4/45.31    | 9/44.38    | 7/43.21    | 6/38.22    |
| POLY-3 PERCENT (g) | 8.8%       | 20.3%      | 16.2%      | 15.7%      |
| TERMINAL (d)       | 4/34 (12%) | 6/33 (18%) | 5/30 (17%) | 4/24 (17%) |
| FIRST INCIDENCE    | 730 (T)    | 575        | 541        | 611        |

**STATISTICAL TESTS**

|                    |         |         |         |         |
|--------------------|---------|---------|---------|---------|
| POLY 3             | P=0.314 | P=0.106 | P=0.233 | P=0.267 |
| POLY 1.5           | P=0.361 | P=0.110 | P=0.245 | P=0.298 |
| POLY 6             | P=0.269 | P=0.103 | P=0.220 | P=0.238 |
| COCH-ARM / FISHERS | P=0.472 | P=0.117 | P=0.262 | P=0.370 |
| MAX-ISO-POLY-3     | P=0.256 | P=0.062 | P=0.152 | P=0.188 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Bone  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 0/45.31   | 0/43.77   | 0/42.47   | 1/37.64   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 2.7%      |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 1/24 (4%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | 730 (T)   |

**STATISTICAL TESTS**

|                    |         |     |     |         |
|--------------------|---------|-----|-----|---------|
| POLY 3             | P=0.177 | (e) | (e) | P=0.463 |
| POLY 1.5           | P=0.184 | (e) | (e) | P=0.475 |
| POLY 6             | P=0.171 | (e) | (e) | P=0.450 |
| COCH-ARM / FISHERS | P=0.198 | (e) | (e) | P=0.500 |
| MAX-ISO-POLY-3     | P=0.123 | (e) | (e) | P=0.158 |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Brain  
Hemorrhage**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 1/50 (2%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 0/45.31   | 0/43.77   | 1/42.47   | 0/37.64   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 2.4%      | 0%        |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 1/30 (3%) | 0/24 (0%) |
| FIRST INCIDENCE    | ---       | ---       | 730 (T)   | ---       |

**STATISTICAL TESTS**

|                    |         |     |         |     |
|--------------------|---------|-----|---------|-----|
| POLY 3             | P=0.616 | (e) | P=0.487 | (e) |
| POLY 1.5           | P=0.642 | (e) | P=0.492 | (e) |
| POLY 6             | P=0.588 | (e) | P=0.481 | (e) |
| COCH-ARM / FISHERS | P=0.694 | (e) | P=0.500 | (e) |
| MAX-ISO-POLY-3     | P=0.408 | (e) | P=0.158 | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Clitoral Gland  
Hyperplasia**

**LESION RATES**

|                    |           |            |            |           |
|--------------------|-----------|------------|------------|-----------|
| OVERALL (a)        | 3/49 (6%) | 5/50 (10%) | 9/49 (18%) | 4/49 (8%) |
| POLY-3 RATE (b)    | 3/44.31   | 5/44.60    | 9/43.07    | 4/38.20   |
| POLY-3 PERCENT (g) | 6.8%      | 11.2%      | 20.9%      | 10.5%     |
| TERMINAL (d)       | 3/33 (9%) | 2/33 (6%)  | 4/30 (13%) | 1/24 (4%) |
| FIRST INCIDENCE    | 730 (T)   | 603        | 607        | 529       |

**STATISTICAL TESTS**

|                    |         |         |          |         |
|--------------------|---------|---------|----------|---------|
| POLY 3             | P=0.280 | P=0.360 | P=0.052  | P=0.419 |
| POLY 1.5           | P=0.317 | P=0.362 | P=0.054  | P=0.443 |
| POLY 6             | P=0.246 | P=0.360 | P=0.050* | P=0.398 |
| COCH-ARM / FISHERS | P=0.418 | P=0.369 | P=0.060  | P=0.500 |
| MAX-ISO-POLY-3     | P=0.193 | P=0.234 | P=0.027* | P=0.290 |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Clitoral Gland  
Inflammation Chronic**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 22/49 (45%) | 26/50 (52%) | 26/49 (53%) | 18/49 (37%) |
| POLY-3 RATE (b)    | 22/44.43    | 26/44.20    | 26/42.20    | 18/38.28    |
| POLY-3 PERCENT (g) | 49.5%       | 58.8%       | 61.6%       | 47%         |
| TERMINAL (d)       | 21/33 (64%) | 22/33 (67%) | 22/30 (73%) | 16/24 (67%) |
| FIRST INCIDENCE    | 701         | 687         | 680         | 142         |

**STATISTICAL TESTS**

|                    |          |         |         |          |
|--------------------|----------|---------|---------|----------|
| POLY 3             | P=0.428N | P=0.246 | P=0.170 | P=0.498N |
| POLY 1.5           | P=0.326N | P=0.270 | P=0.210 | P=0.411N |
| POLY 6             | P=0.527  | P=0.226 | P=0.133 | P=0.589  |
| COCH-ARM / FISHERS | P=0.175N | P=0.307 | P=0.272 | P=0.269N |
| MAX-ISO-POLY-3     | P=0.326N | P=0.184 | P=0.126 | P=0.412N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Coagulating Gland  
Inflammation**

**LESION RATES**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| OVERALL (a)        | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) |
| POLY-3 RATE (b)    | 0/0.00   | 0/0.00   | 0/0.00   | 0/0.00   |
| POLY-3 PERCENT (g) | 0%       | 0%       | 0%       | 0%       |
| TERMINAL (d)       | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) |
| FIRST INCIDENCE    | ---      | ---      | ---      | ---      |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Eye  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 0/45.31   | 0/43.77   | 0/42.47   | 0/37.64   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 0%        |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 0/24 (0%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | ---       |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Eye: Lens  
Cataract**

**LESION RATES**

|                    |           |           |            |           |
|--------------------|-----------|-----------|------------|-----------|
| OVERALL (a)        | 4/50 (8%) | 3/50 (6%) | 5/50 (10%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 4/45.62   | 3/44.20   | 5/42.84    | 2/37.64   |
| POLY-3 PERCENT (g) | 8.8%      | 6.8%      | 11.7%      | 5.3%      |
| TERMINAL (d)       | 3/34 (9%) | 2/33 (6%) | 4/30 (13%) | 2/24 (8%) |
| FIRST INCIDENCE    | 647       | 603       | 628        | 730 (T)   |

**STATISTICAL TESTS**

|                    |          |          |         |          |
|--------------------|----------|----------|---------|----------|
| POLY 3             | P=0.430N | P=0.517N | P=0.461 | P=0.429N |
| POLY 1.5           | P=0.393N | P=0.510N | P=0.477 | P=0.398N |
| POLY 6             | P=0.472N | P=0.524N | P=0.441 | P=0.465N |
| COCH-ARM / FISHERS | P=0.320N | P=0.500N | P=0.500 | P=0.339N |
| MAX-ISO-POLY-3     | P=0.466N | P=0.365N | P=0.331 | P=0.292N |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Harderian Gland  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 1/50 (2%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 0/45.31   | 0/43.77   | 1/42.47   | 2/38.03   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 2.4%      | 5.3%      |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 1/30 (3%) | 1/24 (4%) |
| FIRST INCIDENCE    | ---       | ---       | 730 (T)   | 619       |

**STATISTICAL TESTS**

|                    |          |     |         |         |
|--------------------|----------|-----|---------|---------|
| POLY 3             | P=0.054  | (e) | P=0.487 | P=0.200 |
| POLY 1.5           | P=0.058  | (e) | P=0.492 | P=0.212 |
| POLY 6             | P=0.049* | (e) | P=0.481 | P=0.189 |
| COCH-ARM / FISHERS | P=0.070  | (e) | P=0.500 | P=0.247 |
| MAX-ISO-POLY-3     | P=0.077  | (e) | P=0.158 | P=0.075 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Heart  
Cardiomyopathy**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 35/50 (70%) | 32/50 (64%) | 34/50 (68%) | 21/50 (42%) |
| POLY-3 RATE (b)    | 35/46.22    | 32/44.00    | 34/44.33    | 21/38.10    |
| POLY-3 PERCENT (g) | 75.7%       | 72.7%       | 76.7%       | 55.1%       |
| TERMINAL (d)       | 30/34 (88%) | 29/33 (88%) | 26/30 (87%) | 19/24 (79%) |
| FIRST INCIDENCE    | 633         | 697         | 451         | 611         |

**STATISTICAL TESTS**

|                    |            |          |          |            |
|--------------------|------------|----------|----------|------------|
| POLY 3             | P=0.024N*  | P=0.464N | P=0.559  | P=0.028N*  |
| POLY 1.5           | P=0.012N*  | P=0.402N | P=0.582N | P=0.014N*  |
| POLY 6             | P=0.055N   | P=0.557N | P=0.491  | P=0.061N   |
| COCH-ARM / FISHERS | P=0.003N** | P=0.335N | P=0.500N | P=0.004N** |
| MAX-ISO-POLY-3     | P=0.031N*  | P=0.365N | P=0.452  | P=0.024N*  |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

Heart: Atrium  
Thrombosis

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 1/45.37   | 0/43.77   | 0/42.47   | 0/37.64   |
| POLY-3 PERCENT (g) | 2.2%      | 0%        | 0%        | 0%        |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 0/24 (0%) |
| FIRST INCIDENCE    | 716       | ---       | ---       | ---       |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.285N | P=0.507N | P=0.513N | P=0.537N |
| POLY 1.5           | P=0.292N | P=0.504N | P=0.508N | P=0.525N |
| POLY 6             | P=0.278N | P=0.510N | P=0.520N | P=0.550N |
| COCH-ARM / FISHERS | P=0.306N | P=0.500N | P=0.500N | P=0.500N |
| MAX-ISO-POLY-3     | P=0.192N | P=0.168N | P=0.175N | P=0.204N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Islets, Pancreatic  
Hyperplasia**

**LESION RATES**

|                    |           |           |           |            |
|--------------------|-----------|-----------|-----------|------------|
| OVERALL (a)        | 0/50 (0%) | 3/50 (6%) | 4/50 (8%) | 4/50 (8%)  |
| POLY-3 RATE (b)    | 0/45.31   | 3/43.77   | 4/43.40   | 4/37.64    |
| POLY-3 PERCENT (g) | 0%        | 6.9%      | 9.2%      | 10.6%      |
| TERMINAL (d)       | 0/34 (0%) | 3/33 (9%) | 2/30 (7%) | 4/24 (17%) |
| FIRST INCIDENCE    | ---       | 730 (T)   | 554       | 730 (T)    |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.041* | P=0.112  | P=0.055  | P=0.040* |
| POLY 1.5           | P=0.051  | P=0.115  | P=0.057  | P=0.046* |
| POLY 6             | P=0.032* | P=0.110  | P=0.052  | P=0.034* |
| COCH-ARM / FISHERS | P=0.078  | P=0.121  | P=0.059  | P=0.059  |
| MAX-ISO-POLY-3     | P=0.059  | P=0.038* | P=0.019* | P=0.018* |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Islets, Pancreatic  
Metaplasia Hepatocyte**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 2/50 (4%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 0/45.31   | 0/43.77   | 2/42.87   | 1/37.82   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 4.7%      | 2.6%      |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 1/30 (3%) | 0/24 (0%) |
| FIRST INCIDENCE    | ---       | ---       | 618       | 682       |

**STATISTICAL TESTS**

|                    |         |     |         |         |
|--------------------|---------|-----|---------|---------|
| POLY 3             | P=0.184 | (e) | P=0.225 | P=0.464 |
| POLY 1.5           | P=0.202 | (e) | P=0.230 | P=0.476 |
| POLY 6             | P=0.166 | (e) | P=0.219 | P=0.452 |
| COCH-ARM / FISHERS | P=0.246 | (e) | P=0.247 | P=0.500 |
| MAX-ISO-POLY-3     | P=0.197 | (e) | P=0.076 | P=0.158 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Kidney  
Nephropathy Chronic**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 35/49 (71%) | 35/50 (70%) | 31/50 (62%) | 29/50 (58%) |
| POLY-3 RATE (b)    | 35/46.95    | 35/47.84    | 31/44.95    | 29/40.35    |
| POLY-3 PERCENT (g) | 74.5%       | 73.2%       | 69%         | 71.9%       |
| TERMINAL (d)       | 26/34 (77%) | 24/33 (73%) | 22/30 (73%) | 19/24 (79%) |
| FIRST INCIDENCE    | 493         | 433         | 541         | 450         |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.395N | P=0.533N | P=0.353N | P=0.484N |
| POLY 1.5           | P=0.250N | P=0.527N | P=0.291N | P=0.328N |
| POLY 6             | P=0.507  | P=0.543N | P=0.437N | P=0.544  |
| COCH-ARM / FISHERS | P=0.070N | P=0.526N | P=0.217N | P=0.117N |
| MAX-ISO-POLY-3     | P=0.536N | P=0.436N | P=0.274N | P=0.390N |

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Kidney: Cortex, Renal Tubule  
Casts Granular**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/49 (0%) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 0/44.45   | 0/43.77   | 0/42.47   | 0/37.64   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 0%        |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 0/24 (0%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | ---       |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Kidney: Pelvis  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/49 (0%) | 0/50 (0%) | 1/50 (2%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 0/44.45   | 0/43.77   | 1/42.47   | 0/37.64   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 2.4%      | 0%        |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 1/30 (3%) | 0/24 (0%) |
| FIRST INCIDENCE    | ---       | ---       | 730 (T)   | ---       |

**STATISTICAL TESTS**

|                    |         |     |         |     |
|--------------------|---------|-----|---------|-----|
| POLY 3             | P=0.619 | (e) | P=0.491 | (e) |
| POLY 1.5           | P=0.644 | (e) | P=0.496 | (e) |
| POLY 6             | P=0.590 | (e) | P=0.484 | (e) |
| COCH-ARM / FISHERS | P=0.697 | (e) | P=0.505 | (e) |
| MAX-ISO-POLY-3     | P=0.409 | (e) | P=0.160 | (e) |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

Larynx  
Foreign Body

**LESION RATES**

|                    |            |            |            |           |
|--------------------|------------|------------|------------|-----------|
| OVERALL (a)        | 8/50 (16%) | 6/50 (12%) | 3/50 (6%)  | 4/50 (8%) |
| POLY-3 RATE (b)    | 8/46.48    | 6/43.82    | 3/42.47    | 4/38.37   |
| POLY-3 PERCENT (g) | 17.2%      | 13.7%      | 7.1%       | 10.4%     |
| TERMINAL (d)       | 5/34 (15%) | 5/33 (15%) | 3/30 (10%) | 2/24 (8%) |
| FIRST INCIDENCE    | 493        | 716        | 730 (T)    | 498       |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.168N | P=0.432N | P=0.128N | P=0.283N |
| POLY 1.5           | P=0.149N | P=0.414N | P=0.116N | P=0.245N |
| POLY 6             | P=0.194N | P=0.453N | P=0.146N | P=0.328N |
| COCH-ARM / FISHERS | P=0.113N | P=0.387N | P=0.100N | P=0.178N |
| MAX-ISO-POLY-3     | P=0.224N | P=0.327N | P=0.081N | P=0.209N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Larynx  
Inflammation Chronic**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 18/50 (36%) | 25/50 (50%) | 30/50 (60%) | 35/50 (70%) |
| POLY-3 RATE (b)    | 18/46.35    | 25/45.82    | 30/44.92    | 35/45.48    |
| POLY-3 PERCENT (g) | 38.8%       | 54.6%       | 66.8%       | 77%         |
| TERMINAL (d)       | 15/34 (44%) | 18/33 (55%) | 22/30 (73%) | 17/24 (71%) |
| FIRST INCIDENCE    | 493         | 433         | 541         | 386         |

**STATISTICAL TESTS**

|                    |           |         |           |           |
|--------------------|-----------|---------|-----------|-----------|
| POLY 3             | P<0.001** | P=0.091 | P=0.005** | P<0.001** |
| POLY 1.5           | P<0.001** | P=0.099 | P=0.007** | P<0.001** |
| POLY 6             | P<0.001** | P=0.084 | P=0.003** | P<0.001** |
| COCH-ARM / FISHERS | P<0.001** | P=0.113 | P=0.014*  | P<0.001** |
| MAX-ISO-POLY-3     | P<0.001** | P=0.062 | P=0.003** | P<0.001** |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Larynx  
Metaplasia**

**LESION RATES**

|                    |           |           |            |             |
|--------------------|-----------|-----------|------------|-------------|
| OVERALL (a)        | 3/50 (6%) | 2/50 (4%) | 6/50 (12%) | 21/50 (42%) |
| POLY-3 RATE (b)    | 3/46.15   | 2/43.90   | 6/42.80    | 21/42.71    |
| POLY-3 PERCENT (g) | 6.5%      | 4.6%      | 14%        | 49.2%       |
| TERMINAL (d)       | 1/34 (3%) | 1/33 (3%) | 4/30 (13%) | 8/24 (33%)  |
| FIRST INCIDENCE    | 493       | 697       | 688        | 431         |

**STATISTICAL TESTS**

|                    |           |          |         |           |
|--------------------|-----------|----------|---------|-----------|
| POLY 3             | P<0.001** | P=0.523N | P=0.206 | P<0.001** |
| POLY 1.5           | P<0.001** | P=0.514N | P=0.220 | P<0.001** |
| POLY 6             | P<0.001** | P=0.532N | P=0.190 | P<0.001** |
| COCH-ARM / FISHERS | P<0.001** | P=0.500N | P=0.243 | P<0.001** |
| MAX-ISO-POLY-3     | P<0.001** | P=0.347N | P=0.129 | P<0.001** |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Liver  
Angiectasis**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 3/50 (6%) | 2/50 (4%) | 2/50 (4%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 3/45.31   | 2/43.77   | 2/42.64   | 1/37.64   |
| POLY-3 PERCENT (g) | 6.6%      | 4.6%      | 4.7%      | 2.7%      |
| TERMINAL (d)       | 3/34 (9%) | 2/33 (6%) | 1/30 (3%) | 1/24 (4%) |
| FIRST INCIDENCE    | 730 (T)   | 730 (T)   | 688       | 730 (T)   |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.286N | P=0.516N | P=0.528N | P=0.374N |
| POLY 1.5           | P=0.269N | P=0.509N | P=0.516N | P=0.351N |
| POLY 6             | P=0.305N | P=0.522N | P=0.541N | P=0.400N |
| COCH-ARM / FISHERS | P=0.232N | P=0.500N | P=0.500N | P=0.309N |
| MAX-ISO-POLY-3     | P=0.362N | P=0.340N | P=0.352N | P=0.224N |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Liver  
Basophilic Focus**

**LESION RATES**

|                    |             |             |              |             |
|--------------------|-------------|-------------|--------------|-------------|
| OVERALL (a)        | 40/50 (80%) | 43/50 (86%) | 42/50 (84%)  | 39/50 (78%) |
| POLY-3 RATE (b)    | 40/47.89    | 43/46.52    | 42/45.78     | 39/44.04    |
| POLY-3 PERCENT (g) | 83.5%       | 92.4%       | 91.8%        | 88.6%       |
| TERMINAL (d)       | 30/34 (88%) | 32/33 (97%) | 30/30 (100%) | 21/24 (88%) |
| FIRST INCIDENCE    | 438         | 575         | 534          | 453         |

**STATISTICAL TESTS**

|                    |          |         |         |          |
|--------------------|----------|---------|---------|----------|
| POLY 3             | P=0.322  | P=0.130 | P=0.157 | P=0.336  |
| POLY 1.5           | P=0.419  | P=0.188 | P=0.249 | P=0.411  |
| POLY 6             | P=0.274  | P=0.087 | P=0.076 | P=0.310  |
| COCH-ARM / FISHERS | P=0.354N | P=0.298 | P=0.398 | P=0.500N |
| MAX-ISO-POLY-3     | P=0.168  | P=0.072 | P=0.091 | P=0.236  |

---

TDMS No. 20011 - 05  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 1-Bromopropane  
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008  
 Time Report Requested: 10:20:06  
 First Dose M/F: 07/14/03 / 07/14/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
 TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

Liver  
 Clear Cell Focus

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 30/50 (60%) | 34/50 (68%) | 35/50 (70%) | 35/50 (70%) |
| POLY-3 RATE (b)    | 30/47.28    | 34/46.16    | 35/45.29    | 35/43.47    |
| POLY-3 PERCENT (g) | 63.5%       | 73.7%       | 77.3%       | 80.5%       |
| TERMINAL (d)       | 21/34 (62%) | 26/33 (79%) | 24/30 (80%) | 20/24 (83%) |
| FIRST INCIDENCE    | 633         | 433         | 554         | 386         |

**STATISTICAL TESTS**

|                    |          |         |         |          |
|--------------------|----------|---------|---------|----------|
| POLY 3             | P=0.038* | P=0.193 | P=0.100 | P=0.050* |
| POLY 1.5           | P=0.064  | P=0.226 | P=0.135 | P=0.076  |
| POLY 6             | P=0.022* | P=0.151 | P=0.070 | P=0.031* |
| COCH-ARM / FISHERS | P=0.194  | P=0.266 | P=0.201 | P=0.201  |
| MAX-ISO-POLY-3     | P=0.048* | P=0.139 | P=0.069 | P=0.034* |



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Liver  
Degeneration Cystic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 0/45.31   | 0/43.77   | 0/42.47   | 1/37.64   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 2.7%      |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 1/24 (4%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | 730 (T)   |

**STATISTICAL TESTS**

|                    |         |     |     |         |
|--------------------|---------|-----|-----|---------|
| POLY 3             | P=0.177 | (e) | (e) | P=0.463 |
| POLY 1.5           | P=0.184 | (e) | (e) | P=0.475 |
| POLY 6             | P=0.171 | (e) | (e) | P=0.450 |
| COCH-ARM / FISHERS | P=0.198 | (e) | (e) | P=0.500 |
| MAX-ISO-POLY-3     | P=0.123 | (e) | (e) | P=0.158 |

---

TDMS No. 20011 - 05  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 1-Bromopropane  
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008  
 Time Report Requested: 10:20:06  
 First Dose M/F: 07/14/03 / 07/14/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
 TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

Liver  
 Hepatodiaphragmatic Nodule

**LESION RATES**

|                    |            |            |            |            |
|--------------------|------------|------------|------------|------------|
| OVERALL (a)        | 4/50 (8%)  | 9/50 (18%) | 5/50 (10%) | 5/50 (10%) |
| POLY-3 RATE (b)    | 4/45.31    | 9/43.90    | 5/43.36    | 5/38.82    |
| POLY-3 PERCENT (g) | 8.8%       | 20.5%      | 11.5%      | 12.9%      |
| TERMINAL (d)       | 4/34 (12%) | 8/33 (24%) | 2/30 (7%)  | 3/24 (13%) |
| FIRST INCIDENCE    | 730 (T)    | 697        | 547        | 450        |

**STATISTICAL TESTS**

|                    |          |         |         |         |
|--------------------|----------|---------|---------|---------|
| POLY 3             | P=0.504  | P=0.102 | P=0.472 | P=0.404 |
| POLY 1.5           | P=0.544  | P=0.107 | P=0.483 | P=0.433 |
| POLY 6             | P=0.461  | P=0.096 | P=0.461 | P=0.373 |
| COCH-ARM / FISHERS | P=0.485N | P=0.117 | P=0.500 | P=0.500 |
| MAX-ISO-POLY-3     | P=0.357  | P=0.060 | P=0.340 | P=0.291 |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Liver  
Mixed Cell Focus**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 2/50 (4%) | 2/50 (4%) | 3/50 (6%) | 3/50 (6%) |
| POLY-3 RATE (b)    | 2/45.31   | 2/44.03   | 3/43.26   | 3/38.38   |
| POLY-3 PERCENT (g) | 4.4%      | 4.5%      | 6.9%      | 7.8%      |
| TERMINAL (d)       | 2/34 (6%) | 1/33 (3%) | 1/30 (3%) | 1/24 (4%) |
| FIRST INCIDENCE    | 730 (T)   | 659       | 607       | 626       |

**STATISTICAL TESTS**

|                    |         |          |         |         |
|--------------------|---------|----------|---------|---------|
| POLY 3             | P=0.292 | P=0.684  | P=0.479 | P=0.425 |
| POLY 1.5           | P=0.315 | P=0.687  | P=0.487 | P=0.448 |
| POLY 6             | P=0.270 | P=0.681  | P=0.470 | P=0.402 |
| COCH-ARM / FISHERS | P=0.371 | P=0.691N | P=0.500 | P=0.500 |
| MAX-ISO-POLY-3     | P=0.442 | P=0.488  | P=0.309 | P=0.275 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

Liver  
Necrosis

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 0/50 (0%) | 1/50 (2%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 1/45.31   | 0/43.77   | 1/43.05   | 0/37.64   |
| POLY-3 PERCENT (g) | 2.2%      | 0%        | 2.3%      | 0%        |
| TERMINAL (d)       | 1/34 (3%) | 0/33 (0%) | 0/30 (0%) | 0/24 (0%) |
| FIRST INCIDENCE    | 730 (T)   | ---       | 547       | ---       |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.429N | P=0.507N | P=0.749  | P=0.537N |
| POLY 1.5           | P=0.422N | P=0.504N | P=0.754  | P=0.525N |
| POLY 6             | P=0.436N | P=0.510N | P=0.744  | P=0.550N |
| COCH-ARM / FISHERS | P=0.405N | P=0.500N | P=0.753N | P=0.500N |
| MAX-ISO-POLY-3     | P=0.328N | P=0.167N | P=0.485  | P=0.203N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

Liver  
Vacuolization Cytoplasmic

**LESION RATES**

|                    |             |             |             |              |
|--------------------|-------------|-------------|-------------|--------------|
| OVERALL (a)        | 40/50 (80%) | 41/50 (82%) | 39/50 (78%) | 47/50 (94%)  |
| POLY-3 RATE (b)    | 40/47.44    | 41/47.14    | 39/45.93    | 47/47.85     |
| POLY-3 PERCENT (g) | 84.3%       | 87%         | 84.9%       | 98.2%        |
| TERMINAL (d)       | 29/34 (85%) | 30/33 (91%) | 27/30 (90%) | 24/24 (100%) |
| FIRST INCIDENCE    | 633         | 433         | 547         | 386          |

**STATISTICAL TESTS**

|                    |          |         |          |           |
|--------------------|----------|---------|----------|-----------|
| POLY 3             | P=0.012* | P=0.468 | P=0.589  | P=0.012*  |
| POLY 1.5           | P=0.011* | P=0.486 | P=0.587N | P=0.009** |
| POLY 6             | P=0.017* | P=0.441 | P=0.525  | P=0.020*  |
| COCH-ARM / FISHERS | P=0.038* | P=0.500 | P=0.500N | P=0.036*  |
| MAX-ISO-POLY-3     | P=0.013* | P=0.346 | P=0.466  | P=0.004** |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lung  
Hemorrhage**

**LESION RATES**

|                    |            |            |            |            |
|--------------------|------------|------------|------------|------------|
| OVERALL (a)        | 4/50 (8%)  | 6/50 (12%) | 4/50 (8%)  | 4/50 (8%)  |
| POLY-3 RATE (b)    | 4/45.31    | 6/43.77    | 4/42.66    | 4/37.82    |
| POLY-3 PERCENT (g) | 8.8%       | 13.7%      | 9.4%       | 10.6%      |
| TERMINAL (d)       | 4/34 (12%) | 6/33 (18%) | 3/30 (10%) | 3/24 (13%) |
| FIRST INCIDENCE    | 730 (T)    | 730 (T)    | 681        | 682        |

**STATISTICAL TESTS**

|                    |          |         |          |          |
|--------------------|----------|---------|----------|----------|
| POLY 3             | P=0.540  | P=0.347 | P=0.610  | P=0.541  |
| POLY 1.5           | P=0.545N | P=0.357 | P=0.623  | P=0.574  |
| POLY 6             | P=0.497  | P=0.338 | P=0.595  | P=0.505  |
| COCH-ARM / FISHERS | P=0.467N | P=0.370 | P=0.643N | P=0.643N |
| MAX-ISO-POLY-3     | P=0.585  | P=0.238 | P=0.465  | P=0.401  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Lung  
Inflammation Chronic**

**LESION RATES**

|                    |            |             |             |            |
|--------------------|------------|-------------|-------------|------------|
| OVERALL (a)        | 6/50 (12%) | 10/50 (20%) | 12/50 (24%) | 6/50 (12%) |
| POLY-3 RATE (b)    | 6/45.31    | 10/44.30    | 12/42.89    | 6/39.91    |
| POLY-3 PERCENT (g) | 13.2%      | 22.6%       | 28%         | 15%        |
| TERMINAL (d)       | 6/34 (18%) | 7/33 (21%)  | 9/30 (30%)  | 2/24 (8%)  |
| FIRST INCIDENCE    | 730 (T)    | 632         | 680         | 431        |

**STATISTICAL TESTS**

|                    |          |         |          |          |
|--------------------|----------|---------|----------|----------|
| POLY 3             | P=0.473  | P=0.189 | P=0.071  | P=0.529  |
| POLY 1.5           | P=0.517  | P=0.196 | P=0.080  | P=0.555  |
| POLY 6             | P=0.429  | P=0.185 | P=0.061  | P=0.504  |
| COCH-ARM / FISHERS | P=0.475N | P=0.207 | P=0.096  | P=0.620N |
| MAX-ISO-POLY-3     | P=0.273  | P=0.127 | P=0.045* | P=0.410  |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lung: Alveolar Epithelium  
Hyperplasia**

**LESION RATES**

|                    |             |             |             |            |
|--------------------|-------------|-------------|-------------|------------|
| OVERALL (a)        | 11/50 (22%) | 10/50 (20%) | 16/50 (32%) | 8/50 (16%) |
| POLY-3 RATE (b)    | 11/45.37    | 10/43.77    | 16/44.70    | 8/37.99    |
| POLY-3 PERCENT (g) | 24.3%       | 22.9%       | 35.8%       | 21.1%      |
| TERMINAL (d)       | 10/34 (29%) | 10/33 (30%) | 9/30 (30%)  | 6/24 (25%) |
| FIRST INCIDENCE    | 716         | 730 (T)     | 541         | 682        |

**STATISTICAL TESTS**

|                    |          |          |         |          |
|--------------------|----------|----------|---------|----------|
| POLY 3             | P=0.540  | P=0.538N | P=0.165 | P=0.467N |
| POLY 1.5           | P=0.478N | P=0.522N | P=0.171 | P=0.413N |
| POLY 6             | P=0.470  | P=0.554N | P=0.163 | P=0.524N |
| COCH-ARM / FISHERS | P=0.334N | P=0.500N | P=0.184 | P=0.306N |
| MAX-ISO-POLY-3     | P=0.430N | P=0.437N | P=0.115 | P=0.374N |

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Lung: Alveolus  
Infiltration Cellular Histiocyte**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 30/50 (60%) | 30/50 (60%) | 29/50 (58%) | 26/50 (52%) |
| POLY-3 RATE (b)    | 30/46.91    | 30/45.87    | 29/44.71    | 26/39.58    |
| POLY-3 PERCENT (g) | 64%         | 65.4%       | 64.9%       | 65.7%       |
| TERMINAL (d)       | 24/34 (71%) | 24/33 (73%) | 21/30 (70%) | 18/24 (75%) |
| FIRST INCIDENCE    | 438         | 433         | 541         | 590         |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.481  | P=0.529  | P=0.552  | P=0.523  |
| POLY 1.5           | P=0.469N | P=0.552  | P=0.578N | P=0.531N |
| POLY 6             | P=0.361  | P=0.500  | P=0.516  | P=0.402  |
| COCH-ARM / FISHERS | P=0.212N | P=0.581N | P=0.500N | P=0.273N |
| MAX-ISO-POLY-3     | P=0.671  | P=0.439  | P=0.462  | P=0.433  |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Lymph Node, Bronchial  
Angiectasis**

**LESION RATES**

|                    |            |          |           |           |
|--------------------|------------|----------|-----------|-----------|
| OVERALL (a)        | 1/1 (100%) | 0/4 (0%) | 2/5 (40%) | 1/7 (14%) |
| POLY-3 RATE (b)    | 1/1.00     | 0/2.78   | 2/4.40    | 1/5.59    |
| POLY-3 PERCENT (g) | 100%       | 0%       | 45.5%     | 17.9%     |
| TERMINAL (d)       | 0/0 (0%)   | 0/1 (0%) | 1/2 (50%) | 0/2 (0%)  |
| FIRST INCIDENCE    | 660        | ---      | 684       | 616       |

**STATISTICAL TESTS**

|                    |          |            |          |          |
|--------------------|----------|------------|----------|----------|
| POLY 3             | P=0.254N | P=0.002N** | P=0.549N | P=0.280N |
| POLY 1.5           | P=0.290N | P<0.001N** | P=0.525N | P=0.259N |
| POLY 6             | P=0.240N | P=0.064N   | P=0.593N | P=0.316N |
| COCH-ARM / FISHERS | P=0.357N | P=0.200N   | P=0.500N | P=0.250N |
| MAX-ISO-POLY-3     | P=0.098N | P<0.001N** | P=0.218N | P=0.052N |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node, Bronchial  
Hyperplasia Lymphoid**

**LESION RATES**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| OVERALL (a)        | 0/1 (0%) | 0/4 (0%) | 0/5 (0%) | 0/7 (0%) |
| POLY-3 RATE (b)    | 0/0.74   | 0/2.78   | 0/4.22   | 0/5.19   |
| POLY-3 PERCENT (g) | 0%       | 0%       | 0%       | 0%       |
| TERMINAL (d)       | 0/0 (0%) | 0/1 (0%) | 0/2 (0%) | 0/2 (0%) |
| FIRST INCIDENCE    | ---      | ---      | ---      | ---      |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node, Mediastinal  
Angiectasis**

**LESION RATES**

|                    |           |           |           |            |
|--------------------|-----------|-----------|-----------|------------|
| OVERALL (a)        | 0/34 (0%) | 0/30 (0%) | 2/31 (6%) | 2/28 (7%)  |
| POLY-3 RATE (b)    | 0/31.29   | 0/27.57   | 2/28.22   | 2/21.23    |
| POLY-3 PERCENT (g) | 0%        | 0%        | 7.1%      | 9.4%       |
| TERMINAL (d)       | 0/25 (0%) | 0/22 (0%) | 1/23 (4%) | 2/14 (14%) |
| FIRST INCIDENCE    | ---       | ---       | 451       | 730 (T)    |

**STATISTICAL TESTS**

|                    |          |     |         |         |
|--------------------|----------|-----|---------|---------|
| POLY 3             | P=0.041* | (e) | P=0.213 | P=0.157 |
| POLY 1.5           | P=0.047* | (e) | P=0.214 | P=0.166 |
| POLY 6             | P=0.036* | (e) | P=0.212 | P=0.147 |
| COCH-ARM / FISHERS | P=0.065  | (e) | P=0.224 | P=0.200 |
| MAX-ISO-POLY-3     | P=0.064  | (e) | P=0.070 | P=0.063 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node, Mediastinal Hemorrhage**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/34 (0%) | 0/30 (0%) | 0/31 (0%) | 2/28 (7%) |
| POLY-3 RATE (b)    | 0/31.29   | 0/27.57   | 0/27.46   | 2/22.23   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 9%        |
| TERMINAL (d)       | 0/25 (0%) | 0/22 (0%) | 0/23 (0%) | 1/14 (7%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | 38        |

**STATISTICAL TESTS**

|                    |          |     |     |         |
|--------------------|----------|-----|-----|---------|
| POLY 3             | P=0.031* | (e) | (e) | P=0.165 |
| POLY 1.5           | P=0.032* | (e) | (e) | P=0.174 |
| POLY 6             | P=0.030* | (e) | (e) | P=0.155 |
| COCH-ARM / FISHERS | P=0.036* | (e) | (e) | P=0.200 |
| MAX-ISO-POLY-3     | P=0.024* | (e) | (e) | P=0.063 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node, Mediastinal  
Hyperplasia Lymphoid**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/34 (0%) | 0/30 (0%) | 0/31 (0%) | 0/28 (0%) |
| POLY-3 RATE (b)    | 0/31.29   | 0/27.57   | 0/27.46   | 0/21.23   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 0%        |
| TERMINAL (d)       | 0/25 (0%) | 0/22 (0%) | 0/23 (0%) | 0/14 (0%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | ---       |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node, Mesenteric  
Angiectasis**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/49 (0%) | 0/49 (0%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 0/45.10   | 0/43.56   | 0/42.47   | 0/37.64   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 0%        |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 0/24 (0%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | ---       |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

---

TDMS No. 20011 - 05  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 1-Bromopropane  
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008  
 Time Report Requested: 10:20:06  
 First Dose M/F: 07/14/03 / 07/14/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Lymph Node: Pancreatic  
 Angiectasis**

**LESION RATES**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| OVERALL (a)        | 0/1 (0%) | 0/3 (0%) | 0/2 (0%) | 0/2 (0%) |
| POLY-3 RATE (b)    | 0/1.00   | 0/2.47   | 0/1.41   | 0/1.82   |
| POLY-3 PERCENT (g) | 0%       | 0%       | 0%       | 0%       |
| TERMINAL (d)       | 0/1 (0%) | 0/0 (0%) | 0/1 (0%) | 0/1 (0%) |
| FIRST INCIDENCE    | ---      | ---      | ---      | ---      |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Mammary Gland  
Galactocele**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 0/50 (0%) | 3/50 (6%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 1/45.31   | 0/43.77   | 3/42.62   | 1/37.90   |
| POLY-3 PERCENT (g) | 2.2%      | 0%        | 7%        | 2.6%      |
| TERMINAL (d)       | 1/34 (3%) | 0/33 (0%) | 2/30 (7%) | 0/24 (0%) |
| FIRST INCIDENCE    | 730 (T)   | ---       | 694       | 660       |

**STATISTICAL TESTS**

|                    |         |          |         |          |
|--------------------|---------|----------|---------|----------|
| POLY 3             | P=0.380 | P=0.507N | P=0.283 | P=0.719  |
| POLY 1.5           | P=0.407 | P=0.504N | P=0.292 | P=0.733  |
| POLY 6             | P=0.353 | P=0.510N | P=0.273 | P=0.705  |
| COCH-ARM / FISHERS | P=0.469 | P=0.500N | P=0.309 | P=0.753N |
| MAX-ISO-POLY-3     | P=0.281 | P=0.167N | P=0.146 | P=0.452  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Mesentery  
Necrosis**

**LESION RATES**

|                    |              |              |              |              |
|--------------------|--------------|--------------|--------------|--------------|
| OVERALL (a)        | 13/13 (100%) | 26/26 (100%) | 16/17 (94%)  | 22/23 (96%)  |
| POLY-3 RATE (b)    | 13/13.00     | 26/26.00     | 16/16.42     | 22/22.50     |
| POLY-3 PERCENT (g) | 100%         | 100%         | 97.4%        | 97.8%        |
| TERMINAL (d)       | 10/10 (100%) | 20/20 (100%) | 10/10 (100%) | 12/12 (100%) |
| FIRST INCIDENCE    | 438          | 575          | 417          | 453          |

**STATISTICAL TESTS**

|                    |          |     |          |          |
|--------------------|----------|-----|----------|----------|
| POLY 3             | P=0.464N | (e) | P=0.929N | P=0.904N |
| POLY 1.5           | P=0.354N | (e) | P=0.745N | P=0.761N |
| POLY 6             | P=0.841N | (e) | P=1.000N | P=1.000N |
| COCH-ARM / FISHERS | P=0.287N | (e) | P=0.567N | P=0.639N |
| MAX-ISO-POLY-3     | P=0.338N | (e) | P=0.204N | P=0.253N |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Nose  
Foreign Body**

**LESION RATES**

|                    |            |            |            |            |
|--------------------|------------|------------|------------|------------|
| OVERALL (a)        | 6/50 (12%) | 6/50 (12%) | 6/49 (12%) | 9/50 (18%) |
| POLY-3 RATE (b)    | 6/45.64    | 6/45.02    | 6/41.71    | 9/40.65    |
| POLY-3 PERCENT (g) | 13.2%      | 13.3%      | 14.4%      | 22.1%      |
| TERMINAL (d)       | 5/34 (15%) | 2/33 (6%)  | 5/30 (17%) | 5/24 (21%) |
| FIRST INCIDENCE    | 639        | 575        | 718        | 142        |

**STATISTICAL TESTS**

|                    |         |          |         |         |
|--------------------|---------|----------|---------|---------|
| POLY 3             | P=0.144 | P=0.611  | P=0.557 | P=0.207 |
| POLY 1.5           | P=0.166 | P=0.614  | P=0.577 | P=0.234 |
| POLY 6             | P=0.120 | P=0.612  | P=0.532 | P=0.178 |
| COCH-ARM / FISHERS | P=0.210 | P=0.620N | P=0.606 | P=0.288 |
| MAX-ISO-POLY-3     | P=0.225 | P=0.489  | P=0.434 | P=0.148 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Nose  
Inflammation Chronic**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 24/50 (48%) | 38/50 (76%) | 40/49 (82%) | 43/50 (86%) |
| POLY-3 RATE (b)    | 24/47.26    | 38/47.41    | 40/48.15    | 43/48.34    |
| POLY-3 PERCENT (g) | 50.8%       | 80.2%       | 83.1%       | 89%         |
| TERMINAL (d)       | 17/34 (50%) | 27/33 (82%) | 23/30 (77%) | 20/24 (83%) |
| FIRST INCIDENCE    | 493         | 433         | 417         | 142         |

**STATISTICAL TESTS**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| POLY 3             | P<0.001** | P<0.001** | P<0.001** | P<0.001** |
| POLY 1.5           | P<0.001** | P=0.002** | P<0.001** | P<0.001** |
| POLY 6             | P<0.001** | P<0.001** | P<0.001** | P<0.001** |
| COCH-ARM / FISHERS | P<0.001** | P=0.004** | P<0.001** | P<0.001** |
| MAX-ISO-POLY-3     | P<0.001** | P<0.001** | P<0.001** | P<0.001** |

TDMS No. 20011 - 05  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 1-Bromopropane  
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008  
 Time Report Requested: 10:20:06  
 First Dose M/F: 07/14/03 / 07/14/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Nose: Epithelium  
 Accumulation, Hyaline Droplet**

**LESION RATES**

|                    |             |             |              |             |
|--------------------|-------------|-------------|--------------|-------------|
| OVERALL (a)        | 48/50 (96%) | 48/50 (96%) | 48/49 (98%)  | 47/50 (94%) |
| POLY-3 RATE (b)    | 48/49.67    | 48/49.38    | 48/48.24     | 47/48.01    |
| POLY-3 PERCENT (g) | 96.6%       | 97.2%       | 99.5%        | 97.9%       |
| TERMINAL (d)       | 33/34 (97%) | 32/33 (97%) | 30/30 (100%) | 23/24 (96%) |
| FIRST INCIDENCE    | 438         | 433         | 417          | 386         |

**STATISTICAL TESTS**

|                    |          |          |         |          |
|--------------------|----------|----------|---------|----------|
| POLY 3             | P=0.418  | P=0.673  | P=0.370 | P=0.598  |
| POLY 1.5           | P=0.405  | P=0.679  | P=0.414 | P=0.581  |
| POLY 6             | P=0.485  | P=0.682  | P=0.368 | P=0.655  |
| COCH-ARM / FISHERS | P=0.403N | P=0.691N | P=0.508 | P=0.500N |
| MAX-ISO-POLY-3     | P=0.374  | P=0.429  | P=0.128 | P=0.348  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Nose: Glands  
Hyperplasia**

**LESION RATES**

|                    |            |             |             |             |
|--------------------|------------|-------------|-------------|-------------|
| OVERALL (a)        | 6/50 (12%) | 23/50 (46%) | 28/49 (57%) | 30/50 (60%) |
| POLY-3 RATE (b)    | 6/46.06    | 23/46.65    | 28/46.66    | 30/44.92    |
| POLY-3 PERCENT (g) | 13%        | 49.3%       | 60%         | 66.8%       |
| TERMINAL (d)       | 3/34 (9%)  | 15/33 (46%) | 14/30 (47%) | 11/24 (46%) |
| FIRST INCIDENCE    | 639        | 491         | 417         | 431         |

**STATISTICAL TESTS**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| POLY 3             | P<0.001** | P<0.001** | P<0.001** | P<0.001** |
| POLY 1.5           | P<0.001** | P<0.001** | P<0.001** | P<0.001** |
| POLY 6             | P<0.001** | P<0.001** | P<0.001** | P<0.001** |
| COCH-ARM / FISHERS | P<0.001** | P<0.001** | P<0.001** | P<0.001** |
| MAX-ISO-POLY-3     | P<0.001** | P<0.001** | P<0.001** | P<0.001** |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Nose: Olfactory Epithelium  
Metaplasia Respiratory**

**LESION RATES**

|                    |           |           |            |            |
|--------------------|-----------|-----------|------------|------------|
| OVERALL (a)        | 3/50 (6%) | 4/50 (8%) | 6/49 (12%) | 9/50 (18%) |
| POLY-3 RATE (b)    | 3/45.31   | 4/44.63   | 6/42.64    | 9/39.80    |
| POLY-3 PERCENT (g) | 6.6%      | 9%        | 14.1%      | 22.6%      |
| TERMINAL (d)       | 3/34 (9%) | 1/33 (3%) | 2/30 (7%)  | 6/24 (25%) |
| FIRST INCIDENCE    | 730 (T)   | 575       | 541        | 142        |

**STATISTICAL TESTS**

|                    |          |         |         |          |
|--------------------|----------|---------|---------|----------|
| POLY 3             | P=0.014* | P=0.492 | P=0.212 | P=0.034* |
| POLY 1.5           | P=0.018* | P=0.494 | P=0.220 | P=0.041* |
| POLY 6             | P=0.011* | P=0.492 | P=0.205 | P=0.026* |
| COCH-ARM / FISHERS | P=0.028* | P=0.500 | P=0.233 | P=0.061  |
| MAX-ISO-POLY-3     | P=0.021* | P=0.341 | P=0.131 | P=0.022* |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Nose: Respiratory Epithelium  
Hyperplasia**

**LESION RATES**

|                    |            |             |            |             |
|--------------------|------------|-------------|------------|-------------|
| OVERALL (a)        | 5/50 (10%) | 13/50 (26%) | 9/49 (18%) | 18/50 (36%) |
| POLY-3 RATE (b)    | 5/45.31    | 13/45.20    | 9/41.89    | 18/42.19    |
| POLY-3 PERCENT (g) | 11%        | 28.8%       | 21.5%      | 42.7%       |
| TERMINAL (d)       | 5/34 (15%) | 7/33 (21%)  | 7/30 (23%) | 10/24 (42%) |
| FIRST INCIDENCE    | 730 (T)    | 575         | 684        | 142         |

**STATISTICAL TESTS**

|                    |           |          |         |           |
|--------------------|-----------|----------|---------|-----------|
| POLY 3             | P<0.001** | P=0.030* | P=0.149 | P<0.001** |
| POLY 1.5           | P=0.002** | P=0.030* | P=0.162 | P<0.001** |
| POLY 6             | P<0.001** | P=0.030* | P=0.136 | P<0.001** |
| COCH-ARM / FISHERS | P=0.004** | P=0.033* | P=0.183 | P=0.002** |
| MAX-ISO-POLY-3     | P<0.001** | P=0.016* | P=0.098 | P<0.001** |



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Nose: Respiratory Epithelium  
Metaplasia**

**LESION RATES**

|                    |           |           |            |           |
|--------------------|-----------|-----------|------------|-----------|
| OVERALL (a)        | 1/50 (2%) | 1/50 (2%) | 5/49 (10%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 1/45.57   | 1/43.77   | 5/42.43    | 1/38.03   |
| POLY-3 PERCENT (g) | 2.2%      | 2.3%      | 11.8%      | 2.6%      |
| TERMINAL (d)       | 0/34 (0%) | 1/33 (3%) | 3/30 (10%) | 0/24 (0%) |
| FIRST INCIDENCE    | 660       | 730 (T)   | 541        | 619       |

**STATISTICAL TESTS**

|                    |         |          |          |          |
|--------------------|---------|----------|----------|----------|
| POLY 3             | P=0.372 | P=0.752  | P=0.085  | P=0.719  |
| POLY 1.5           | P=0.411 | P=0.755  | P=0.090  | P=0.733  |
| POLY 6             | P=0.331 | P=0.748  | P=0.080  | P=0.703  |
| COCH-ARM / FISHERS | P=0.499 | P=0.753N | P=0.098  | P=0.753N |
| MAX-ISO-POLY-3     | P=0.244 | P=0.488  | P=0.040* | P=0.452  |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Oral Mucosa  
Foreign Body**

**LESION RATES**

|                    |          |          |            |            |
|--------------------|----------|----------|------------|------------|
| OVERALL (a)        | 0/2 (0%) | 0/0 (0%) | 1/1 (100%) | 1/1 (100%) |
| POLY-3 RATE (b)    | 0/2.00   | 0/0.00   | 1/1.00     | 1/1.00     |
| POLY-3 PERCENT (g) | 0%       | 0%       | 100%       | 100%       |
| TERMINAL (d)       | 0/2 (0%) | 0/0 (0%) | 1/1 (100%) | 1/1 (100%) |
| FIRST INCIDENCE    | ---      | ---      | 730 (T)    | 730 (T)    |

**STATISTICAL TESTS**

|                    |         |     |           |           |
|--------------------|---------|-----|-----------|-----------|
| POLY 3             | (e)     | (e) | P=0.333   | P=0.333   |
| POLY 1.5           | (e)     | (e) | P=0.333   | P=0.333   |
| POLY 6             | (e)     | (e) | P=0.333   | P=0.333   |
| COCH-ARM / FISHERS | P=0.114 | (e) | P=0.333   | P=0.333   |
| MAX-ISO-POLY-3     | (e)     | (e) | P<0.001** | P<0.001** |

TDMS No. 20011 - 05  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 1-Bromopropane  
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008  
 Time Report Requested: 10:20:06  
 First Dose M/F: 07/14/03 / 07/14/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Oral Mucosa  
 Hyperplasia**

**LESION RATES**

|                    |            |          |            |            |
|--------------------|------------|----------|------------|------------|
| OVERALL (a)        | 2/2 (100%) | 0/0 (0%) | 1/1 (100%) | 1/1 (100%) |
| POLY-3 RATE (b)    | 2/2.00     | 0/0.00   | 1/1.00     | 1/1.00     |
| POLY-3 PERCENT (g) | 100%       | 0%       | 100%       | 100%       |
| TERMINAL (d)       | 2/2 (100%) | 0/0 (0%) | 1/1 (100%) | 1/1 (100%) |
| FIRST INCIDENCE    | 730 (T)    | ---      | 730 (T)    | 730 (T)    |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Oral Mucosa  
Inflammation Chronic**

**LESION RATES**

|                    |          |          |          |            |
|--------------------|----------|----------|----------|------------|
| OVERALL (a)        | 0/2 (0%) | 0/0 (0%) | 0/1 (0%) | 1/1 (100%) |
| POLY-3 RATE (b)    | 0/2.00   | 0/0.00   | 0/1.00   | 1/1.00     |
| POLY-3 PERCENT (g) | 0%       | 0%       | 0%       | 100%       |
| TERMINAL (d)       | 0/2 (0%) | 0/0 (0%) | 0/1 (0%) | 1/1 (100%) |
| FIRST INCIDENCE    | ---      | ---      | ---      | 730 (T)    |

**STATISTICAL TESTS**

|                    |         |     |     |           |
|--------------------|---------|-----|-----|-----------|
| POLY 3             | (e)     | (e) | (e) | P=0.333   |
| POLY 1.5           | (e)     | (e) | (e) | P=0.333   |
| POLY 6             | (e)     | (e) | (e) | P=0.333   |
| COCH-ARM / FISHERS | P=0.148 | (e) | (e) | P=0.333   |
| MAX-ISO-POLY-3     | (e)     | (e) | (e) | P<0.001** |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Ovary  
Cyst**

**LESION RATES**

|                    |           |           |            |            |
|--------------------|-----------|-----------|------------|------------|
| OVERALL (a)        | 3/50 (6%) | 1/50 (2%) | 7/50 (14%) | 3/50 (6%)  |
| POLY-3 RATE (b)    | 3/45.49   | 1/43.77   | 7/43.11    | 3/37.64    |
| POLY-3 PERCENT (g) | 6.6%      | 2.3%      | 16.2%      | 8%         |
| TERMINAL (d)       | 2/34 (6%) | 1/33 (3%) | 4/30 (13%) | 3/24 (13%) |
| FIRST INCIDENCE    | 683       | 730 (T)   | 607        | 730 (T)    |

**STATISTICAL TESTS**

|                    |         |          |         |          |
|--------------------|---------|----------|---------|----------|
| POLY 3             | P=0.261 | P=0.319N | P=0.135 | P=0.572  |
| POLY 1.5           | P=0.300 | P=0.314N | P=0.144 | P=0.602  |
| POLY 6             | P=0.221 | P=0.325N | P=0.125 | P=0.537  |
| COCH-ARM / FISHERS | P=0.389 | P=0.309N | P=0.159 | P=0.661N |
| MAX-ISO-POLY-3     | P=0.188 | P=0.169N | P=0.080 | P=0.412  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Pancreas: Acinus Atrophy**

**LESION RATES**

|                    |            |             |            |            |
|--------------------|------------|-------------|------------|------------|
| OVERALL (a)        | 9/50 (18%) | 12/50 (24%) | 7/50 (14%) | 7/50 (14%) |
| POLY-3 RATE (b)    | 9/45.31    | 12/44.60    | 7/43.41    | 7/38.91    |
| POLY-3 PERCENT (g) | 19.9%      | 26.9%       | 16.1%      | 18%        |
| TERMINAL (d)       | 9/34 (27%) | 9/33 (27%)  | 4/30 (13%) | 4/24 (17%) |
| FIRST INCIDENCE    | 730 (T)    | 575         | 554        | 529        |

**STATISTICAL TESTS**

|                    |          |         |          |          |
|--------------------|----------|---------|----------|----------|
| POLY 3             | P=0.330N | P=0.294 | P=0.428N | P=0.524N |
| POLY 1.5           | P=0.294N | P=0.301 | P=0.415N | P=0.484N |
| POLY 6             | P=0.367N | P=0.291 | P=0.442N | P=0.563N |
| COCH-ARM / FISHERS | P=0.216N | P=0.312 | P=0.393N | P=0.393N |
| MAX-ISO-POLY-3     | P=0.408N | P=0.217 | P=0.327N | P=0.418N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Parathyroid Gland  
Hyperplasia**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/47 (0%) | 0/48 (0%) | 0/47 (0%) | 0/46 (0%) |
| POLY-3 RATE (b)    | 0/42.31   | 0/41.93   | 0/40.48   | 0/34.46   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 0%        |
| TERMINAL (d)       | 0/31 (0%) | 0/32 (0%) | 0/29 (0%) | 0/22 (0%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | ---       |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Pituitary Gland  
Cyst**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 2/50 (4%) | 1/50 (2%) | 2/50 (4%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 2/45.37   | 1/43.77   | 2/42.83   | 2/38.68   |
| POLY-3 PERCENT (g) | 4.4%      | 2.3%      | 4.7%      | 5.2%      |
| TERMINAL (d)       | 1/34 (3%) | 1/33 (3%) | 0/30 (0%) | 0/24 (0%) |
| FIRST INCIDENCE    | 716       | 730 (T)   | 680       | 501       |

**STATISTICAL TESTS**

|                    |         |          |          |          |
|--------------------|---------|----------|----------|----------|
| POLY 3             | P=0.461 | P=0.513N | P=0.673  | P=0.635  |
| POLY 1.5           | P=0.480 | P=0.507N | P=0.681  | P=0.653  |
| POLY 6             | P=0.441 | P=0.518N | P=0.664  | P=0.616  |
| COCH-ARM / FISHERS | P=0.526 | P=0.500N | P=0.691N | P=0.691N |
| MAX-ISO-POLY-3     | P=0.556 | P=0.294N | P=0.476  | P=0.439  |



TDMS No. 20011 - 05  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 1-Bromopropane  
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008  
 Time Report Requested: 10:20:06  
 First Dose M/F: 07/14/03 / 07/14/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
 TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Pituitary Gland  
 Hemorrhage**

**LESION RATES**

|                    |           |            |            |           |
|--------------------|-----------|------------|------------|-----------|
| OVERALL (a)        | 2/50 (4%) | 4/50 (8%)  | 5/50 (10%) | 3/50 (6%) |
| POLY-3 RATE (b)    | 2/45.31   | 4/43.77    | 5/43.46    | 3/38.74   |
| POLY-3 PERCENT (g) | 4.4%      | 9.1%       | 11.5%      | 7.7%      |
| TERMINAL (d)       | 2/34 (6%) | 4/33 (12%) | 3/30 (10%) | 1/24 (4%) |
| FIRST INCIDENCE    | 730 (T)   | 730 (T)    | 541        | 529       |

**STATISTICAL TESTS**

|                    |         |         |         |         |
|--------------------|---------|---------|---------|---------|
| POLY 3             | P=0.350 | P=0.321 | P=0.199 | P=0.429 |
| POLY 1.5           | P=0.383 | P=0.328 | P=0.206 | P=0.450 |
| POLY 6             | P=0.318 | P=0.314 | P=0.191 | P=0.407 |
| COCH-ARM / FISHERS | P=0.463 | P=0.339 | P=0.218 | P=0.500 |
| MAX-ISO-POLY-3     | P=0.338 | P=0.192 | P=0.112 | P=0.278 |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Pituitary Gland: Pars Distalis  
Hyperplasia**

**LESION RATES**

|                    |            |             |            |            |
|--------------------|------------|-------------|------------|------------|
| OVERALL (a)        | 7/50 (14%) | 11/50 (22%) | 7/50 (14%) | 7/50 (14%) |
| POLY-3 RATE (b)    | 7/46.05    | 11/44.86    | 7/43.06    | 7/38.07    |
| POLY-3 PERCENT (g) | 15.2%      | 24.5%       | 16.3%      | 18.4%      |
| TERMINAL (d)       | 4/34 (12%) | 8/33 (24%)  | 5/30 (17%) | 6/24 (25%) |
| FIRST INCIDENCE    | 633        | 528         | 618        | 606        |

**STATISTICAL TESTS**

|                    |          |         |          |          |
|--------------------|----------|---------|----------|----------|
| POLY 3             | P=0.523  | P=0.197 | P=0.561  | P=0.462  |
| POLY 1.5           | P=0.514N | P=0.205 | P=0.583  | P=0.512  |
| POLY 6             | P=0.454  | P=0.188 | P=0.535  | P=0.406  |
| COCH-ARM / FISHERS | P=0.397N | P=0.218 | P=0.613N | P=0.613N |
| MAX-ISO-POLY-3     | P=0.497  | P=0.135 | P=0.446  | P=0.360  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Salivary Glands  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 0/45.31   | 0/43.77   | 0/42.47   | 1/38.11   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 2.6%      |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 0/24 (0%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | 590       |

**STATISTICAL TESTS**

|                    |         |     |     |         |
|--------------------|---------|-----|-----|---------|
| POLY 3             | P=0.179 | (e) | (e) | P=0.466 |
| POLY 1.5           | P=0.185 | (e) | (e) | P=0.476 |
| POLY 6             | P=0.173 | (e) | (e) | P=0.454 |
| COCH-ARM / FISHERS | P=0.198 | (e) | (e) | P=0.500 |
| MAX-ISO-POLY-3     | P=0.123 | (e) | (e) | P=0.158 |

TDMS No. 20011 - 05  
 Test Type: CHRONIC  
 Route: RESPIRATORY EXPOSURE WHOLE BODY  
 Species/Strain: RATS/F 344

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS  
 1-Bromopropane  
 CAS Number: 106-94-5

Date Report Requested: 07/09/2008  
 Time Report Requested: 10:20:06  
 First Dose M/F: 07/14/03 / 07/14/03  
 Lab: BNW

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
 TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Skin  
 Hyperkeratosis**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 2/50 (4%) | 2/50 (4%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 1/45.31   | 2/43.77   | 2/42.65   | 0/37.64   |
| POLY-3 PERCENT (g) | 2.2%      | 4.6%      | 4.7%      | 0%        |
| TERMINAL (d)       | 1/34 (3%) | 2/33 (6%) | 1/30 (3%) | 0/24 (0%) |
| FIRST INCIDENCE    | 730 (T)   | 730 (T)   | 684       | ---       |

**STATISTICAL TESTS**

|                    |          |         |         |          |
|--------------------|----------|---------|---------|----------|
| POLY 3             | P=0.367N | P=0.488 | P=0.479 | P=0.537N |
| POLY 1.5           | P=0.344N | P=0.493 | P=0.487 | P=0.525N |
| POLY 6             | P=0.393N | P=0.483 | P=0.469 | P=0.550N |
| COCH-ARM / FISHERS | P=0.296N | P=0.500 | P=0.500 | P=0.500N |
| MAX-ISO-POLY-3     | P=0.291N | P=0.273 | P=0.269 | P=0.203N |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Skin  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 3/50 (6%) | 1/50 (2%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 1/45.31   | 3/43.93   | 1/42.47   | 1/37.64   |
| POLY-3 PERCENT (g) | 2.2%      | 6.8%      | 2.4%      | 2.7%      |
| TERMINAL (d)       | 1/34 (3%) | 2/33 (6%) | 1/30 (3%) | 1/24 (4%) |
| FIRST INCIDENCE    | 730 (T)   | 687       | 730 (T)   | 730 (T)   |

**STATISTICAL TESTS**

|                    |          |         |          |          |
|--------------------|----------|---------|----------|----------|
| POLY 3             | P=0.510N | P=0.294 | P=0.746  | P=0.718  |
| POLY 1.5           | P=0.489N | P=0.299 | P=0.752  | P=0.732  |
| POLY 6             | P=0.535N | P=0.290 | P=0.739  | P=0.701  |
| COCH-ARM / FISHERS | P=0.444N | P=0.309 | P=0.753N | P=0.753N |
| MAX-ISO-POLY-3     | P=0.526N | P=0.150 | P=0.481  | P=0.451  |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Spleen  
Fibrosis**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 0/45.31   | 0/43.77   | 0/42.47   | 0/37.64   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 0%        |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 0/24 (0%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | ---       |

**STATISTICAL TESTS**

|                    |     |     |     |     |
|--------------------|-----|-----|-----|-----|
| POLY 3             | (e) | (e) | (e) | (e) |
| POLY 1.5           | (e) | (e) | (e) | (e) |
| POLY 6             | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e) | (e) | (e) | (e) |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Spleen  
Hematopoietic Cell Proliferation**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 33/50 (66%) | 32/50 (64%) | 29/50 (58%) | 21/50 (42%) |
| POLY-3 RATE (b)    | 33/47.62    | 32/45.28    | 29/43.77    | 21/39.08    |
| POLY-3 PERCENT (g) | 69.3%       | 70.7%       | 66.3%       | 53.7%       |
| TERMINAL (d)       | 27/34 (79%) | 26/33 (79%) | 23/30 (77%) | 16/24 (67%) |
| FIRST INCIDENCE    | 438         | 577         | 547         | 578         |

**STATISTICAL TESTS**

|                    |            |          |          |           |
|--------------------|------------|----------|----------|-----------|
| POLY 3             | P=0.057N   | P=0.534  | P=0.463N | P=0.093N  |
| POLY 1.5           | P=0.028N*  | P=0.585  | P=0.379N | P=0.051N  |
| POLY 6             | P=0.112N   | P=0.487  | P=0.566N | P=0.161N  |
| COCH-ARM / FISHERS | P=0.006N** | P=0.500N | P=0.268N | P=0.013N* |
| MAX-ISO-POLY-3     | P=0.089N   | P=0.440  | P=0.376N | P=0.077N  |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | CONTROL | Females |         |         |
|------|---------|---------|---------|---------|
|      |         | 125 PPM | 250 PPM | 500 PPM |

---

**Spleen  
Hemorrhage Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 0/50 (0%) | 1/50 (2%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 1/45.64   | 0/43.77   | 1/43.07   | 2/37.82   |
| POLY-3 PERCENT (g) | 2.2%      | 0%        | 2.3%      | 5.3%      |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 1/24 (4%) |
| FIRST INCIDENCE    | 639       | ---       | 541       | 682       |

**STATISTICAL TESTS**

|                    |         |          |          |         |
|--------------------|---------|----------|----------|---------|
| POLY 3             | P=0.211 | P=0.508N | P=0.748  | P=0.435 |
| POLY 1.5           | P=0.222 | P=0.505N | P=0.753  | P=0.456 |
| POLY 6             | P=0.200 | P=0.512N | P=0.741  | P=0.412 |
| COCH-ARM / FISHERS | P=0.247 | P=0.500N | P=0.753N | P=0.500 |
| MAX-ISO-POLY-3     | P=0.210 | P=0.169N | P=0.483  | P=0.247 |

---



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Spleen  
Infarct Chronic**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 1/50 (2%) | 1/50 (2%) | 1/50 (2%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 1/45.37   | 1/43.77   | 1/42.65   | 1/37.80   |
| POLY-3 PERCENT (g) | 2.2%      | 2.3%      | 2.3%      | 2.7%      |
| TERMINAL (d)       | 0/34 (0%) | 1/33 (3%) | 0/30 (0%) | 0/24 (0%) |
| FIRST INCIDENCE    | 716       | 730 (T)   | 684       | 688       |

**STATISTICAL TESTS**

|                    |         |          |          |          |
|--------------------|---------|----------|----------|----------|
| POLY 3             | P=0.570 | P=0.753  | P=0.747  | P=0.718  |
| POLY 1.5           | P=0.590 | P=0.756  | P=0.752  | P=0.732  |
| POLY 6             | P=0.548 | P=0.749  | P=0.740  | P=0.703  |
| COCH-ARM / FISHERS | P=0.634 | P=0.753N | P=0.753N | P=0.753N |
| MAX-ISO-POLY-3     | P=0.692 | P=0.489  | P=0.482  | P=0.451  |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Spleen  
Inflammation Granulomatous**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 2/50 (4%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 0/45.31   | 2/43.77   | 0/42.47   | 0/37.64   |
| POLY-3 PERCENT (g) | 0%        | 4.6%      | 0%        | 0%        |
| TERMINAL (d)       | 0/34 (0%) | 2/33 (6%) | 0/30 (0%) | 0/24 (0%) |
| FIRST INCIDENCE    | ---       | 730 (T)   | ---       | ---       |

**STATISTICAL TESTS**

|                    |          |         |     |     |
|--------------------|----------|---------|-----|-----|
| POLY 3             | P=0.442N | P=0.229 | (e) | (e) |
| POLY 1.5           | P=0.429N | P=0.233 | (e) | (e) |
| POLY 6             | P=0.457N | P=0.226 | (e) | (e) |
| COCH-ARM / FISHERS | P=0.405N | P=0.247 | (e) | (e) |
| MAX-ISO-POLY-3     | P=0.317N | P=0.076 | (e) | (e) |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Stomach, Forestomach  
Hyperplasia**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 4/50 (8%) | 0/50 (0%) | 2/50 (4%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 4/46.08   | 0/43.77   | 2/42.65   | 2/38.91   |
| POLY-3 PERCENT (g) | 8.7%      | 0%        | 4.7%      | 5.1%      |
| TERMINAL (d)       | 1/34 (3%) | 0/33 (0%) | 1/30 (3%) | 0/24 (0%) |
| FIRST INCIDENCE    | 633       | ---       | 684       | 386       |

**STATISTICAL TESTS**

|                    |          |           |          |          |
|--------------------|----------|-----------|----------|----------|
| POLY 3             | P=0.436N | P=0.067N  | P=0.373N | P=0.418N |
| POLY 1.5           | P=0.427N | P=0.064N  | P=0.358N | P=0.391N |
| POLY 6             | P=0.448N | P=0.071N  | P=0.393N | P=0.450N |
| COCH-ARM / FISHERS | P=0.404N | P=0.059N  | P=0.339N | P=0.339N |
| MAX-ISO-POLY-3     | P=0.219N | P=0.025N* | P=0.237N | P=0.281N |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Stomach, Forestomach  
Ulcer**

**LESION RATES**

|                    |           |           |           |            |
|--------------------|-----------|-----------|-----------|------------|
| OVERALL (a)        | 2/50 (4%) | 3/50 (6%) | 3/50 (6%) | 6/50 (12%) |
| POLY-3 RATE (b)    | 2/45.67   | 3/45.01   | 3/43.20   | 6/40.12    |
| POLY-3 PERCENT (g) | 4.4%      | 6.7%      | 6.9%      | 15%        |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 1/30 (3%) | 0/24 (0%)  |
| FIRST INCIDENCE    | 647       | 433       | 554       | 386        |

**STATISTICAL TESTS**

|                    |          |         |         |         |
|--------------------|----------|---------|---------|---------|
| POLY 3             | P=0.055  | P=0.493 | P=0.475 | P=0.094 |
| POLY 1.5           | P=0.062  | P=0.496 | P=0.485 | P=0.105 |
| POLY 6             | P=0.048* | P=0.490 | P=0.462 | P=0.084 |
| COCH-ARM / FISHERS | P=0.080  | P=0.500 | P=0.500 | P=0.134 |
| MAX-ISO-POLY-3     | P=0.073  | P=0.319 | P=0.306 | P=0.056 |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Stomach, Glandular  
Ulcer**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 3/50 (6%) | 1/50 (2%) | 1/50 (2%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 3/46.05   | 1/43.93   | 1/43.05   | 1/38.03   |
| POLY-3 PERCENT (g) | 6.5%      | 2.3%      | 2.3%      | 2.6%      |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 0/24 (0%) |
| FIRST INCIDENCE    | 633       | 687       | 547       | 619       |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.270N | P=0.322N | P=0.330N | P=0.377N |
| POLY 1.5           | P=0.261N | P=0.315N | P=0.319N | P=0.353N |
| POLY 6             | P=0.280N | P=0.330N | P=0.343N | P=0.404N |
| COCH-ARM / FISHERS | P=0.242N | P=0.309N | P=0.309N | P=0.309N |
| MAX-ISO-POLY-3     | P=0.290N | P=0.172N | P=0.179N | P=0.226N |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Thyroid Gland: C-Cell  
Hyperplasia**

**LESION RATES**

|                    |             |             |             |             |
|--------------------|-------------|-------------|-------------|-------------|
| OVERALL (a)        | 39/50 (78%) | 36/50 (72%) | 37/50 (74%) | 37/50 (74%) |
| POLY-3 RATE (b)    | 39/47.92    | 36/45.51    | 37/45.78    | 37/44.21    |
| POLY-3 PERCENT (g) | 81.4%       | 79.1%       | 80.8%       | 83.7%       |
| TERMINAL (d)       | 30/34 (88%) | 28/33 (85%) | 26/30 (87%) | 20/24 (83%) |
| FIRST INCIDENCE    | 438         | 575         | 451         | 386         |

**STATISTICAL TESTS**

|                    |          |          |          |          |
|--------------------|----------|----------|----------|----------|
| POLY 3             | P=0.393  | P=0.493N | P=0.583N | P=0.493  |
| POLY 1.5           | P=0.449  | P=0.422N | P=0.512N | P=0.555  |
| POLY 6             | P=0.362  | P=0.564N | P=0.592  | P=0.458  |
| COCH-ARM / FISHERS | P=0.424N | P=0.322N | P=0.408N | P=0.408N |
| MAX-ISO-POLY-3     | P=0.526  | P=0.385N | P=0.470N | P=0.380  |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Thyroid Gland: Follicular Cell  
Hyperplasia**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 1/50 (2%) | 2/50 (4%) | 0/50 (0%) |
| POLY-3 RATE (b)    | 0/45.31   | 1/43.77   | 2/42.67   | 0/37.64   |
| POLY-3 PERCENT (g) | 0%        | 2.3%      | 4.7%      | 0%        |
| TERMINAL (d)       | 0/34 (0%) | 1/33 (3%) | 1/30 (3%) | 0/24 (0%) |
| FIRST INCIDENCE    | ---       | 730 (T)   | 680       | ---       |

**STATISTICAL TESTS**

|                    |          |         |         |     |
|--------------------|----------|---------|---------|-----|
| POLY 3             | P=0.589  | P=0.493 | P=0.224 | (e) |
| POLY 1.5           | P=0.622  | P=0.496 | P=0.229 | (e) |
| POLY 6             | P=0.551  | P=0.490 | P=0.218 | (e) |
| COCH-ARM / FISHERS | P=0.616N | P=0.500 | P=0.247 | (e) |
| MAX-ISO-POLY-3     | P=0.356  | P=0.158 | P=0.076 | (e) |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Trachea  
Inflammation Chronic**

**LESION RATES**

|                    |           |           |           |            |
|--------------------|-----------|-----------|-----------|------------|
| OVERALL (a)        | 0/50 (0%) | 4/50 (8%) | 1/50 (2%) | 6/50 (12%) |
| POLY-3 RATE (b)    | 0/45.31   | 4/44.90   | 1/42.47   | 6/39.91    |
| POLY-3 PERCENT (g) | 0%        | 8.9%      | 2.4%      | 15%        |
| TERMINAL (d)       | 0/34 (0%) | 2/33 (6%) | 1/30 (3%) | 2/24 (8%)  |
| FIRST INCIDENCE    | ---       | 528       | 730 (T)   | 431        |

**STATISTICAL TESTS**

|                    |           |          |         |           |
|--------------------|-----------|----------|---------|-----------|
| POLY 3             | P=0.012*  | P=0.059  | P=0.487 | P=0.010** |
| POLY 1.5           | P=0.014*  | P=0.060  | P=0.492 | P=0.011*  |
| POLY 6             | P=0.010** | P=0.059  | P=0.481 | P=0.008** |
| COCH-ARM / FISHERS | P=0.020*  | P=0.059  | P=0.500 | P=0.013*  |
| MAX-ISO-POLY-3     | P=0.005** | P=0.019* | P=0.158 | P=0.004** |



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Trachea: Epithelium  
Hyperplasia**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 4/50 (8%) |
| POLY-3 RATE (b)    | 0/45.31   | 0/43.77   | 0/42.47   | 4/38.74   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 10.3%     |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 2/24 (8%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | 529       |

**STATISTICAL TESTS**

|                    |           |     |     |          |
|--------------------|-----------|-----|-----|----------|
| POLY 3             | P=0.002** | (e) | (e) | P=0.043* |
| POLY 1.5           | P=0.002** | (e) | (e) | P=0.048* |
| POLY 6             | P=0.002** | (e) | (e) | P=0.038* |
| COCH-ARM / FISHERS | P=0.003** | (e) | (e) | P=0.059  |
| MAX-ISO-POLY-3     | P=0.003** | (e) | (e) | P=0.019* |

---

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Uterus  
Decidual Reaction**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 2/50 (4%) |
| POLY-3 RATE (b)    | 0/45.31   | 0/43.77   | 0/42.47   | 2/38.32   |
| POLY-3 PERCENT (g) | 0%        | 0%        | 0%        | 5.2%      |
| TERMINAL (d)       | 0/34 (0%) | 0/33 (0%) | 0/30 (0%) | 1/24 (4%) |
| FIRST INCIDENCE    | ---       | ---       | ---       | 501       |

**STATISTICAL TESTS**

|                    |          |     |     |         |
|--------------------|----------|-----|-----|---------|
| POLY 3             | P=0.040* | (e) | (e) | P=0.202 |
| POLY 1.5           | P=0.041* | (e) | (e) | P=0.213 |
| POLY 6             | P=0.038* | (e) | (e) | P=0.191 |
| COCH-ARM / FISHERS | P=0.046* | (e) | (e) | P=0.247 |
| MAX-ISO-POLY-3     | P=0.032* | (e) | (e) | P=0.075 |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

**Uterus  
Hemorrhage**

**LESION RATES**

|                    |           |           |           |           |
|--------------------|-----------|-----------|-----------|-----------|
| OVERALL (a)        | 0/50 (0%) | 2/50 (4%) | 0/50 (0%) | 1/50 (2%) |
| POLY-3 RATE (b)    | 0/45.31   | 2/44.20   | 0/42.47   | 1/37.64   |
| POLY-3 PERCENT (g) | 0%        | 4.5%      | 0%        | 2.7%      |
| TERMINAL (d)       | 0/34 (0%) | 1/33 (3%) | 0/30 (0%) | 1/24 (4%) |
| FIRST INCIDENCE    | ---       | 603       | ---       | 730 (T)   |

**STATISTICAL TESTS**

|                    |         |         |     |         |
|--------------------|---------|---------|-----|---------|
| POLY 3             | P=0.474 | P=0.232 | (e) | P=0.463 |
| POLY 1.5           | P=0.496 | P=0.234 | (e) | P=0.475 |
| POLY 6             | P=0.451 | P=0.230 | (e) | P=0.450 |
| COCH-ARM / FISHERS | P=0.539 | P=0.247 | (e) | P=0.500 |
| MAX-ISO-POLY-3     | P=0.332 | P=0.076 | (e) | P=0.158 |

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F 344)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

| DOSE | Females |         |         |         |
|------|---------|---------|---------|---------|
|      | CONTROL | 125 PPM | 250 PPM | 500 PPM |

---

**Vagina: Muscularis Hypertrophy**

**LESION RATES**

|                    |            |          |          |          |
|--------------------|------------|----------|----------|----------|
| OVERALL (a)        | 2/3 (67%)  | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) |
| POLY-3 RATE (b)    | 2/2.31     | 0/0.00   | 0/0.00   | 0/0.00   |
| POLY-3 PERCENT (g) | 86.7%      | 0%       | 0%       | 0%       |
| TERMINAL (d)       | 2/2 (100%) | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) |
| FIRST INCIDENCE    | 730 (T)    | ---      | ---      | ---      |

**STATISTICAL TESTS**

|                    |          |     |     |     |
|--------------------|----------|-----|-----|-----|
| POLY 3             | (e)      | (e) | (e) | (e) |
| POLY 1.5           | (e)      | (e) | (e) | (e) |
| POLY 6             | (e)      | (e) | (e) | (e) |
| COCH-ARM / FISHERS | P=1.000N | (e) | (e) | (e) |
| MAX-ISO-POLY-3     | (e)      | (e) | (e) | (e) |

---

**LEGEND**

- (a) Number of tumor-bearing animals/number of animals examined at site.
  - (b) Number of tumor-bearing animals/Poly-3 number
  - (d) Observed incidence at terminal kill.
  - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
  - (e) Value of Statistic cannot be computed.
  - (g) Poly-3 adjusted lifetime tumor incidence.
  - (I) Interim sacrifice
  - (T) Terminal sacrifice
  - # Tumor rates based on numbers of animals necropsied.
  - \* To the right of any statistical result, indicates significance at ( $P \leq 0.05$ ).
  - \*\* To the right of any statistical result, indicates significance at ( $P \leq 0.01$ ).
  - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.  
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

\*\*\* END OF REPORT \*\*\*